<SEC-DOCUMENT>0001104659-23-129018.txt : 20231226
<SEC-HEADER>0001104659-23-129018.hdr.sgml : 20231226
<ACCEPTANCE-DATETIME>20231226092908
ACCESSION NUMBER:		0001104659-23-129018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		22
CONFORMED PERIOD OF REPORT:	20231221
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231226
DATE AS OF CHANGE:		20231226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		231511485

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2333683d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:cycc="http://cyclacel.com/20231221">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_cycc_cyclacel.com_20231221 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20231221_20231221 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001130166 -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\DocumentInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:EntityCentralIndexKey">0001130166</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cycc-20231221.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-12-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-21</xbrli:startDate>
        <xbrli:endDate>2023-12-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-212023-12-21_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-21</xbrli:startDate>
        <xbrli:endDate>2023-12-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-212023-12-21_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-21</xbrli:startDate>
        <xbrli:endDate>2023-12-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="text-align: center; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span id="xdx_901_edei--DocumentType_c20231221__20231221_z7SGdyMhSzI5"><ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Pursuant to Section 13
or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>of the Securities Exchange
Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Date of Report (Date
of earliest event reported): <span id="xdx_906_edei--DocumentPeriodEndDate_c20231221__20231221_zVMVOsduXW9f"><ix:nonNumeric contextRef="AsOf2023-12-21" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 21,
2023</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90B_edei--EntityRegistrantName_c20231221__20231221_z9YIPyfWQcb9" style="font-size: 14pt"><b><ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:EntityRegistrantName">CYCLACEL
PHARMACEUTICALS, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Exact name of registrant
as specified in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 32%; text-align: center"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20231221__20231221_zCWc8TeKyl41" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2023-12-21" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span id="xdx_902_edei--EntityFileNumber_c20231221__20231221_z1yE5h3zxBRh" style="font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:EntityFileNumber">0-50626</ix:nonNumeric></b></span></td>
    <td style="vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20231221__20231221_z9nqSDFzs4qi" style="font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:EntityTaxIdentificationNumber">91-1707622</ix:nonNumeric></b></span></td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top"><b>(State
or other jurisdiction<br />
of incorporation)</b></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(Commission File Number)</b></span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: top"><b>(IRS
Employer<br />
Identification No.)</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_909_edei--EntityAddressAddressLine1_c20231221__20231221_z7O5y1Q7vtj6"><b><ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:EntityAddressAddressLine1">200
Connell Drive</ix:nonNumeric></b></span><b>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20231221__20231221_zHA2DSZJIrV7"><ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:EntityAddressAddressLine2">Suite 1500</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_903_edei--EntityAddressCityOrTown_c20231221__20231221_z8fmyAvBcC6h"><b><ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:EntityAddressCityOrTown">Berkeley
Heights</ix:nonNumeric></b></span><b>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20231221__20231221_zRLUxCCH9nQf"><ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></b><b> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20231221__20231221_zjGhCTyMDm7g"><ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:EntityAddressPostalZipCode">07922</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Address of principal
executive offices and zip code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Registrant&#8217;s telephone
number, including area code: (<span id="xdx_908_edei--CityAreaCode_c20231221__20231221_zOpaxlglAS9f"><ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:CityAreaCode">908</ix:nonNumeric></span></b><b>) <span id="xdx_902_edei--LocalPhoneNumber_c20231221__20231221_zg6YWSFF483g"><ix:nonNumeric contextRef="AsOf2023-12-21" name="dei:LocalPhoneNumber">517-7330</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Former Name or Former
Address, if Changed Since Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see </i>General Instruction A.2. below): </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_902_edei--WrittenCommunications_c20231221__20231221_zmYfLdfZL9Bb" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2023-12-21" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Written
                                            communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_909_edei--SolicitingMaterial_c20231221__20231221_zIlfVAXxFjLf" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2023-12-21" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_908_edei--PreCommencementTenderOffer_c20231221__20231221_z8G0iKsj91o5" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2023-12-21" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20231221__20231221_z9NYFY3Eq7xe" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2023-12-21" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Pre-commencement
                                            communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Securities
registered pursuant to Section&#160;12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 40%"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 20%"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 40%"><span style="font-size: 10pt"><b>Name of each exchange on which registered
    </b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span id="xdx_909_edei--Security12bTitle_c20231221__20231221__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zQpiF4ML1KKj" style="font-size: 10pt"><ix:nonNumeric contextRef="From2023-12-212023-12-21_us-gaap_CommonStockMember" name="dei:Security12bTitle">Common
    Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td><span id="xdx_906_edei--TradingSymbol_c20231221__20231221__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zKDav0lvusqb" style="font-size: 10pt"><ix:nonNumeric contextRef="From2023-12-212023-12-21_us-gaap_CommonStockMember" name="dei:TradingSymbol">CYCC</ix:nonNumeric></span></td>
    <td><span style="font-size: 10pt">The <span id="xdx_90A_edei--SecurityExchangeName_c20231221__20231221__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zQSCEgZHxGRj"><ix:nonNumeric contextRef="From2023-12-212023-12-21_us-gaap_CommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  <tr style="vertical-align: top">
    <td><span id="xdx_90D_edei--Security12bTitle_c20231221__20231221__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zNVJtBXhaH6i" style="font-size: 10pt"><ix:nonNumeric contextRef="From2023-12-212023-12-21_us-gaap_PreferredStockMember" name="dei:Security12bTitle">Preferred
    Stock, $0.001 par value</ix:nonNumeric></span></td>
    <td><span id="xdx_909_edei--TradingSymbol_c20231221__20231221__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z9CveOtRmmD4" style="font-size: 10pt"><ix:nonNumeric contextRef="From2023-12-212023-12-21_us-gaap_PreferredStockMember" name="dei:TradingSymbol">CYCCP</ix:nonNumeric></span></td>
    <td><span style="font-size: 10pt">The <span id="xdx_900_edei--SecurityExchangeName_c20231221__20231221__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zAejgnyCjOhh"><ix:nonNumeric contextRef="From2023-12-212023-12-21_us-gaap_PreferredStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Emerging
growth company&#160;&#160;<span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20231221__20231221_zMcQCxmVWJDc" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2023-12-21" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 1.01.</b></span></td>
    <td style="font-size: 10pt; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry into a Material Definitive Agreement. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Registered Direct Offering and Concurrent Private Placement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December&#160;21, 2023, Cyclacel Pharmaceuticals,&#160;Inc. (the
&#8220;Company,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) entered into a securities purchase agreement (&#8220;Securities Purchase
Agreement&#8221;) with certain institutional investors (&#8220;Purchasers&#8221;). Pursuant to the Securities Purchase Agreement, the
Company agreed to sell in a registered direct offering (&#8220;Registered Direct Offering&#8221;) 168,500 shares (&#8220;Shares&#8221;)
of the Company&#8217;s common stock, $0.001 par value per share (&#8220;Common Stock&#8221;), and pre-funded warrants (&#8220;Pre-Funded
Warrants&#8221;) to purchase up to 219,700 shares of Common Stock, which Pre-Funded Warrants are issued to the extent that the applicable
Purchaser determines, in its sole discretion, that such Purchaser would beneficially own in excess of 4.99% (or at the Purchaser&#8217;s
election, 9.99%). The Pre-Funded Warrants have an exercise price of $0.001 per share and are immediately exercisable and can be exercised
at any time after their original issuance until such Pre-Funded Warrants are exercised in full. Each Share is being sold at an offering
price of $3.315 and each Pre-Funded Warrant is being sold at an offering price of $3.314 (equal to the purchase price per Share minus
the exercise price of the Pre-Funded Warrant).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Securities Purchase Agreement, in a concurrent private
placement (together with the Registered Direct Offering, the &#8220;Offerings&#8221;), the Company also agreed to issue to the Purchasers
unregistered warrants (&#8220;Common Warrants&#8221;) to purchase up to 388,200 shares of Common Stock. Each Common Warrant has an exercise
price of $3.19 per share, is exercisable immediately following their original issuance and will expire seven years from the original issuance
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladenburg Thalmann&#160;&amp; Co. Inc. (the &#8220;Placement Agent&#8221;)
acted as the exclusive placement agent for the Offerings, pursuant to a placement agency agreement (the &#8220;Placement Agency Agreement&#8221;),
dated December&#160;21, 2023, by and between the Company and the Placement Agent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We received aggregate proceeds, before deducting Placement Agent fees,
in the amount of approximately $1.29 million. We intend to use the net proceeds from the Offerings for working capital and general corporate
purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The closing of the Offerings is expected to take place on December&#160;26,
2023 (the &#8220;Closing Date&#8221;), subject to customary closing conditions. The Shares and the Pre-Funded Warrants are being offered
and sold pursuant to our shelf registration statement on Form&#160;S-3 (File No.&#160;333-274328) initially filed with the Securities
and Exchange Commission (the &#8220;Commission&#8221;) on September&#160;1, 2023 and declared effective on September&#160;13, 2023. A
prospectus supplement relating to the Registered Direct Offering was filed with the Commission on December&#160;22, 2023. None of the
Common Warrants or the shares of Common Stock issuable upon the exercise of the Common Warrants are registered under the Securities Act
of 1933 as amended (the &#8220;Securities Act&#8221;). The Common Warrants and shares of Common Stock issuable upon exercise thereof will
be issued in reliance on the exemptions from registration provided by Section&#160;4(a)(2)&#160;under the Securities Act and Regulation
D promulgated thereunder for transactions not involving a public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Securities Purchase Agreement, we have agreed to file
within 30 days following the date of the Securities Purchase Agreement, a registration statement on Form&#160;S-1 providing for the resale
by holders of shares of Common Stock issuable upon the exercise of the Common Warrants, and we will be required to have such resale registration
statement effective by the 60th day following the Closing Date (or, in the event of a &#8220;full review&#8221; by the Commission, the
90th calendar day following the Closing Date). Further, we agreed to use best efforts to keep such registration statement effective at
all times until no Purchaser owns any Common Warrants or shares of Common Stock issued upon exercise of the Common Warrants.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Securities Purchase Agreement contains customary representations,
warranties and agreements by us and customary conditions to closing. Under the Securities Purchase Agreement, and subject to certain exceptions,
we have agreed not to (i)&#160;enter into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or
Common Stock equivalents, or (ii)&#160;file any registration statement or amendment or supplement thereto, for a period of 30 days following
the closing of the Offerings. We have also agreed not to effect or enter into an agreement to effect any issuance of Common Stock or Common
Stock equivalents involving a Variable Rate Transaction, as defined in the Securities Purchase Agreement, for a period of 180 days following
the effective date of the registration statement covering the resale of the shares underlying the Common Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Placement Agency Agreement, we have agreed to pay the
Placement Agent a cash placement fee equal to 8.0% of the aggregate gross proceeds raised in the Offerings from sales arranged for by
the Placement Agent. Subject to certain conditions, we also have agreed to reimburse all reasonable travel and other out-of-pocket expenses
of the Placement Agent in connection with the Offerings, including but not limited to legal fees, up to a maximum of $85,000. In addition,
the Placement Agent will also receive warrants that have substantially the same terms as the Warrants issued in the concurrent private
placement to the Purchasers in the Offerings to purchase that number of shares of Common Stock equal to 6.0% of the aggregate number of
shares of Common Stock and Prefunded Warrants sold in the Offerings, or an aggregate of 23,292 shares of Common Stock, at an exercise
price of $4.14375 per share (the &#8220;Placement Agent Warrants&#8221;). The Placement Agent Warrants will be exercisable immediately
following the date of issuance and will expire five years from issuance. The Placement Agency Agreement contains customary representations,
warranties and agreements by us and customary conditions to closing. We have agreed to indemnify the Placement Agent against certain liabilities,
including liabilities under the Securities Act, and liabilities arising from breaches of representations and warranties contained in the
Placement Agency Agreement, or to contribute to payments that the Placement Agent may be required to make in respect of those liabilities.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concurrent Insider Private Placement</i></b></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December&#160;21, 2023, in a separate concurrent insider private
placement (the &#8220;Insider Private Placement&#8221;), we also entered into a Securities Purchase Agreement with certain of our executive
officers (the &#8220;Insider Securities Purchase Agreement&#8221;) pursuant to which we agreed to sell in a private placement (i)&#160;6,070
shares of Common Stock and warrants to purchase 6,070 shares of Common Stock on the same terms as the Common Warrants issued to the Purchasers
in the Offerings to Spiro Rombotis, our Chief Executive Officer, and (ii)&#160;1,886 shares of Common Stock and warrants to purchase 1,886
shares of Common Stock on the same terms as the Common Warrants issued to the Purchasers in the Offerings to Paul McBarron, our Executive
Vice President-Finance, Chief Financial Officer and Chief Operating Officer. Each such share of Common Stock and accompanying warrant
was sold at a purchase price of $3.315, which was the same purchase price for the Shares sold in the Registered Direct Offering.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing descriptions of the Pre-Funded Warrant, Common Warrant,
Placement Agency Agreement, the Securities Purchase Agreement and the Insider Securities Purchase Agreement do not purport to be complete
and are qualified in their entirety by reference to the full text of the form of Pre-Funded Warrant, form of Common Warrant, the Placement
Agency Agreement, the Securities Purchase Agreement and the Insider Securities Purchase Agreement, which are attached to this Current
Report on Form&#160;8-K as Exhibits 4.1, 4.2, 10.1, 10.2 and 10.3, respectively, and incorporated herein by reference in their entirety.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We note that the representations, warranties and covenants made by
us in any agreement that is filed as an exhibit to any document that is incorporated by reference in the prospectus supplement or the
accompanying base prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose
of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to or in
favor of any stockholder or potential stockholder of the Company other than the parties thereto. In addition, the assertions embodied
in any representations, warranties and covenants contained in such agreements may be subject to qualifications with respect to knowledge
and materiality different from those applicable to security holders generally. Moreover, such representations, warranties or covenants
were accurate only as of the date when made, except where expressly stated otherwise. Accordingly, such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs at any time.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the legal opinion of Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C. relating to the validity of the Shares of Common Stock, the Pre-Funded Warrants and shares of Common Stock underlying
the Pre-Funded Warrants being issued and sold in the Registered Direct Offering by the Company is filed as Exhibit&#160;5.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 3.02</b></span></td>
    <td style="font-size: 10pt; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sale of Unregistered Securities. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information contained in Item 1.01 of this Current Report on Form&#160;8-K
in relation to the concurrent private placement to the Purchasers of Common Warrants and the shares of Common Stock underlying such Common
Warrants and the shares of Common Stock, warrants and shares of Common Stock underlying such warrants issued in the Insider Private Placement
is incorporated herein by reference.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 7.01.</b></span></td>
    <td style="text-align: justify; font-size: 10pt; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation FD Disclosure. </b></span></td></tr>
  </table>
<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On December&#160;22, 2023, the Company issued a press release announcing
the pricing of the Offerings, as described above in Item 1.01 of this Current Report on Form&#160;8-K. The full text of the press release
is attached as Exhibit&#160;99.1 to this Current Report on Form&#160;8-K and is incorporated herein by reference.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with General Instruction B.2 of Form&#160;8-K, the information
contained or incorporated in this Item 7.01, including the press release furnished herewith as Exhibit&#160;99.1, shall not be deemed
&#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;),
or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under
the Securities Act, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly
set forth by specific reference in such a filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span></td>
    <td style="font-size: 10pt; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;<span style="text-decoration: underline">Exhibits</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: center; white-space: nowrap">Exhibit <br />
No.</td>
<td style="font-size: 10pt; width: 1%">&#160;</td>
<td style="white-space: nowrap; font-size: 10pt; width: 93%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
<tr>
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></a></td>
<td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
<td style="vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Pre-Funded Common Stock Purchase Warrant </span></a></td></tr>
<tr>
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></a></td>
<td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
<td style="vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Common Stock Purchase Warrant </span></a></td></tr>
<tr>
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
<td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
<td style="vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.&#160;&#160;</span></a></td></tr>
<tr>
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
<td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
<td style="vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agency Agreement by and between the Company and Ladenburg Thalmann&#160;&amp; Co. Inc., dated December&#160;21, 2023 </span></a></td></tr>
<tr>
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></a></td>
<td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
<td style="vertical-align: top"><a href="tm2333683d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, </span><span style="text-decoration: underline">dated December&#160;21, 2023, by and among the Company and the Purchasers</span> &#160;</a></td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top; font-size: 10pt">&#160;</td>
<td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
<td style="vertical-align: top">&#160;</td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></a></td>
<td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
<td style="vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, </span><span style="text-decoration: underline">dated December&#160;21, 2023, by and among the Company and Spiro Rombotis and Paul McBarron</span></a></td></tr>
<tr>
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
<td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
<td style="vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.&#160;&#160;(contained in opinion filed as Exhibit&#160;5.1 hereto). </span></a></td></tr>
<tr>
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
<td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
<td style="vertical-align: top; font-size: 10pt"><a href="tm2333683d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated December&#160;22, 2023 </span></a></td></tr>
<tr>
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr>
<td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
<td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
<td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (formatted in Inline XBRL and contained in Exhibit&#160;101)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYCLACEL PHARMACEUTICALS,&#160;INC.</b></span></td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid; font-size: 10pt; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul McBarron</span></td>
    <td style="font-size: 10pt; width: 50%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul McBarron</span></td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President-Finance,</span></td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Chief Operating Officer</span></td>
    <td style="font-size: 10pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: December&#160;26, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2OkylH/IyKYksQiS6XXKKJd2R2dXqkXrLViUaDgwzZ745QkxESltVIcNlnWdQYN1U0iLkeENGfUV3kez2Mbie410Zy1LbYfyBCTkGHTP3V9Lth8tOGSxjCBbTyCmEYBXPlnA6CK/3E9I3VaK2SlYgdQknpoYVWsnv8UMhX6Spfg9JZ2SjSMcQ+sFofyAKwgiO1Mkn8cNAliXCmwzliZSpbfqY1liqYVNh7bLMiP7lfQHn+Ekq -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm2333683d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PRE-FUNDED COMMON STOCK
PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CYCLACEL
PHARMACEUTICALS,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares: _______</FONT></TD>
  <TD STYLE="text-align: left; width: 27%"><FONT STYLE="font-size: 10pt">Issue Date:</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; width: 73%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 27%">Initial Exercise Date: December 26, 2023</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is exercised in full (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Cyclacel Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the
 &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common
Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;1</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated December 21, 2023, among the Company and the purchasers signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;2</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement
Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate
Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn
on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the applicable
Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and
the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon
as reasonably practicable of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant
resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver
any objection to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice. <B>The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion
of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the
amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The
Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance
or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.001, subject
to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in
which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 1in; text-align: left; width: 16%">(A)&nbsp;=</TD>
  <TD STYLE="text-align: justify; width: 84%">as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the
  applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof
  on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day
  prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under
  the federal securities laws) on such Trading Day or (ii)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as
  reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice
  of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within
  two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular trading hours&rdquo; on a Trading
  Day) pursuant to Section&nbsp;2(a)&nbsp;hereof;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 1in; text-align: justify; width: 16%">(B)&nbsp;=</TD>
  <TD STYLE="text-align: justify; width: 84%">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 1in; text-align: justify; width: 16%">(X)&nbsp;=</TD>
  <TD STYLE="text-align: justify; width: 84%">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance
  with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of
the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&#8239;&#8239;The
Company agrees not to take any position contrary to this Section&nbsp;2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.&nbsp;(New York
City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.&nbsp;(New
York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if the OTCQB Venture Market (&ldquo;OTCQB&rdquo;) or the OTCQX Best
Market (&ldquo;OTCQX&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX
and if prices for the Common Stock are then reported on the Pink Open Market (&ldquo;Pink Market&rdquo;) operated by the OTC Markets,&nbsp;Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such
system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by the Holder or (B)&nbsp;the Warrant Shares are exercised via a cashless exercise, and otherwise by physical delivery
of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by
the date that is the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one
(1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)&nbsp;the number of Trading Days comprising
the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery
Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the
earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following
delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice
of Exercise by the Warrant Share Delivery Date, provided that the Holder has delivered the Exercise Price (other than in the case of
a cashless exercise), the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant
Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading
Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such
Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain
a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein,
 &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is due to any action or inaction
by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an open market
transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying
(1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of
the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have
been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock
with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial
ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement
by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was
reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [9.99/4.99%] of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of
this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply
to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;3</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to
the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company (or any Subsidiary),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding
Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common
Stock or greater than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of Common Stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate
Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock
for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on
the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company
shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with
the provisions of this Section&nbsp;3(d)&nbsp;pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation
of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor
Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto
and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and
the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally,
had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this
Section&nbsp;3(d)&nbsp;regardless of (i)&nbsp;whether the Company has sufficient authorized shares of Common Stock for the issuance of
Warrant Shares and/or (ii)&nbsp;whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its
last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date
on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and
the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly
set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;4</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section&nbsp;4(d)&nbsp;hereof and to the provisions
of Section&nbsp;4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as
applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new
Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned
this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3)&nbsp;Trading Days of the
date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;5</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of
issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all
Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase
rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which
results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>CYCLACEL PHARMACEUTICALS,&nbsp;INC.</B></FONT> &nbsp; &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
<TD STYLE="width: 3%">By:</TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Title: &nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT><FONT STYLE="text-transform: uppercase">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CYCLACEL
PHARMACEUTICALS,&nbsp;INC.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT>&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the
following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(4)&#8239;&#8239; <U>Accredited
Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act
of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-right: 2pt; white-space: nowrap; text-align: left; width: 10%">Name of Investing Entity: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#8239;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-right: 2pt; white-space: nowrap; text-align: left; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature of Authorized Signatory of Investing Entity</I></FONT>: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#8239;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-right: 2pt; white-space: nowrap; text-align: left; width: 10%">Name of Authorized Signatory:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#8239;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-right: 2pt; white-space: nowrap; text-align: left; width: 10%">Title of Authorized Signatory: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#8239;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-right: 2pt; white-space: nowrap; text-align: left; width: 4%">Date: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 405.75pt"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>(To assign the foregoing Warrant, execute
this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 47%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
<TD STYLE="width: 48%; font-size: 10pt; text-align: justify"></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-top: Black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify"></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-top: Black 1pt solid">(Please Print)</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>Phone Number:</TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>Email Address: </TD>
    <TD>&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: _______________
__, ______</FONT></TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Signature:<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</U></FONT></TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Address:<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</U></FONT></TD>
    <TD>&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>tm2333683d1_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&#8239;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES FOR
WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY&#8239;NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND
IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY&#8239;BE
PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CYCLACEL
PHARMACEUTICALS,&#8239;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares: _______</FONT></TD>
  <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">Issue Date:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&#8239;</TD>
  <TD>&#8239;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&#8239;</TD>
  <TD>Initial Exercise Date: December 26, 2023</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or December
26, 2023 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m.&#8239;(New York City time) on December 26, 2030
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Cyclacel Pharmaceuticals,&#8239;Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section&#8239;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&#8239;1</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated December 21, 2023, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> Insert the date that is the seven year anniversary of the Initial Exercise Date, provided that, if such date is not
a Trading Day, insert the immediately following Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&#8239;2</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i)&#8239;two (2)&#8239;Trading Days and (ii)&#8239;the number of Trading Days comprising the Standard Settlement
Period (as defined in Section&#8239;2(d)(i)&#8239;herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate
Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn
on a United States bank unless the cashless exercise procedure specified in Section&#8239;2(c)&#8239;below is specified in the applicable
Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and
the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon
as reasonably practicable of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant
resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver
any objection to any Notice of Exercise within one (1)&#8239;Business Day of receipt of such notice. <B>The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion
of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the
amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$3.19</B>, subject to adjustment hereunder (the
 &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.35in; text-align: justify; text-indent: -0.35in">(A)&#8239;= as
applicable: (i)&#8239;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1)&#8239;both executed and delivered pursuant to Section&#8239;2(a)&#8239;hereof on a day that is not a Trading Day or (2)&#8239;both
executed and delivered pursuant to Section&#8239;2(a)&#8239;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule&#8239;600(b)&#8239;of Regulation NMS promulgated under the federal securities laws) on such Trading Day or (ii)&#8239;the
Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the
time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2)&#8239;hours thereafter (including until two (2)&#8239;hours after
the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section&#8239;2(a)&#8239;hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.35in; text-align: justify; text-indent: -0.35in">(B)&#8239;= the
Exercise Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.35in; text-align: justify; text-indent: -0.35in">(X)&#8239;= the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&#8239;3(a)(9)&#8239;of the Securities
Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&#8239;&#8239;The Company
agrees not to take any position contrary to this Section&#8239;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&#8239;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.&#8239;(New York
City time) to 4:02 p.m.&#8239;(New York City time)), (b)&#8239; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&#8239;if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&#8239;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&#8239;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.&#8239;(New
York City time) to 4:02 p.m.&#8239;(New York City time)), (b)&#8239; if the OTCQB Venture Market (&ldquo;OTCQB&rdquo;) or the OTCQX Best
Market (&ldquo;OTCQX&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on OTCQB or OTCQX as applicable, (c)&#8239;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX
and if prices for the Common Stock are then reported on the Pink Open Market (&ldquo;Pink Market&rdquo;) operated by the OTC Markets,&#8239;Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&#8239;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section&#8239;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such
system and either (A)&#8239;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by the Holder or (B)&#8239;the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
limitations pursuant to Rule&#8239;144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earliest of (i)&#8239;two (2)&#8239;Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&#8239;one (1)&#8239;Trading
Day after delivery of the aggregate Exercise Price to the Company and (iii)&#8239;the number of Trading Days comprising the Standard Settlement
Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier
of (i)&#8239;two (2)&#8239;Trading Days and (ii)&#8239;the number of Trading Days comprising the Standard Settlement Period following delivery
of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise
by the Warrant Share Delivery Date, provided that the Holder has delivered the Exercise Price (other than in the case of a cashless exercise),
the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to
such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing
to $20 per Trading Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent
that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard
Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&#8239;2(d)(i)&#8239;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&#8239;2(d)(i)&#8239;above
pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is due to any action or inaction
by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an open market
transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A)&#8239;pay in cash to the Holder the amount, if any, by which (x)&#8239;the Holder&rsquo;s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&#8239;the amount obtained by multiplying
(1)&#8239;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2)&#8239;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&#8239;at the option of
the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have
been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock
with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&#8239;of the immediately preceding sentence
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form&#8239;attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&#8239;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#8239; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&#8239;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&#8239;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&#8239; Except as set forth in the preceding sentence, for purposes of this Section&#8239;2(e), beneficial
ownership shall be calculated in accordance with Section&#8239;13(d)&#8239;of the Exchange Act and the rules&#8239;and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section&#8239;13(d)&#8239;of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section&#8239;2(e)&#8239;applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&#8239;13(d)&#8239;of
the Exchange Act and the rules&#8239;and regulations promulgated thereunder. For purposes of this Section&#8239;2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&#8239;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&#8239;a more recent public announcement
by the Company or (C)&#8239;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding.&#8239; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding.&#8239; In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was
reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [9.99/4.99%] of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&#8239;2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of
this Section&#8239;2(e)&#8239;shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section&#8239;2(e)&#8239;to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply
to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&#8239;3</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&#8239;pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&#8239;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&#8239;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&#8239;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&#8239;3(a)&#8239;shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&#8239;3(a)&#8239;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to
the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&#8239;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&#8239;the Company (or any Subsidiary),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&#8239;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding
Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv)&#8239;the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v)&#8239;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common
Stock or greater than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section&#8239;2(e)&#8239;on the exercise of this Warrant), the number of shares of Common Stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate
Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock
for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&#8239;2(e)&#8239;on
the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at
the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction
(or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of
this Warrant on the date of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental
Transaction is not within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be
entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at
the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of
the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination
thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection
with the Fundamental Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or
paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of
the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black
Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo;
function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting
(A)&#8239;a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public
announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B)&#8239;an expected volatility equal to
the greater of (1)&#8239;the 30 day volatility, (2)&#8239;the 100 day volatility or (3)&#8239;the 365 day volatility, each of clauses (1)-(3)&#8239;as
obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following
the public announcement of the applicable contemplated Fundamental Transaction, (C)&#8239;the underlying price per share used in such
calculation shall be the greater of (i)&#8239;the sum of the price per share being offered in cash, if any, plus the value of any non-cash
consideration, if any, being offered in such Fundamental Transaction and (ii)&#8239;the VWAP immediately preceding the public announcement
of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and
(D)&#8239;the remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental
Transaction and the Termination Date and (E)&#8239;a zero cost of borrow. The payment of the Black Scholes Value will be made by wire
transfer of immediately available funds (or such other consideration) within the later of (i)&#8239;five Business Days of the Holder&rsquo;s
election and (ii)&#8239;the date of consummation of the Fundamental Transaction.] The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations
of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section&#8239;3(d)&#8239;pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead
to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor
Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity
or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents
with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the
Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section&#8239;3(d)&#8239;regardless
of (i)&#8239;whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii)&#8239;whether
a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&#8239;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&#8239;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&#8239;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&#8239;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&#8239;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&#8239;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&#8239;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&#8239;the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its
last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x)&#8239;the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&#8239;the date
on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and
the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form&#8239;8-K. The Holder shall remain entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly
set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&#8239;4</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section&#8239;4(d)&#8239;hereof and to the provisions
of Section&#8239;4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as
applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new
Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned
this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3)&#8239;Trading Days of the
date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned
in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&#8239;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original issue date and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i)&#8239;registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii)&#8239;eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule&#8239;144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee
of this Warrant, as the case may be, comply with the provisions of Section&#8239;5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&#8239;5</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&#8239;2(d)(i), except as expressly
set forth in Section&#8239;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&#8239;2(c)&#8239;or to receive cash payments pursuant to Section&#8239;2(d)(i)&#8239;and Section&#8239;2(d)(iv)&#8239;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&#8239;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of
issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all
Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase
rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&#8239;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&#8239;take all such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&#8239;use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which
results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&#8239;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">CYCLACEL
    PHARMACEUTICALS,&#8239;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: &#8239;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT><FONT STYLE="text-transform: uppercase">&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">CYCLACEL
PHARMACEUTICALS,&#8239;INC.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"> <FONT STYLE="font-family: Wingdings">&#168;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"> <FONT STYLE="font-family: Wingdings">&#168;</FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the
following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(4)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Accredited
Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act
of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-right: 2pt; white-space: nowrap; text-align: justify; width: 10%">Name of Investing Entity: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-right: 2pt; white-space: nowrap; text-align: justify; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature of Authorized Signatory of Investing Entity</I></FONT>: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-right: 2pt; white-space: nowrap; text-align: justify; width: 10%">Name of Authorized Signatory:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-right: 2pt; white-space: nowrap; text-align: justify; width: 10%">Title of Authorized Signatory: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-right: 2pt; white-space: nowrap; text-align: justify; width: 4%">Date: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 405.75pt"><B>EXHIBIT&#8239;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>(To assign the foregoing Warrant, execute
this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Phone Number:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Email Address:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">(Please
        Print)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>
        <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P>
        <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:______________________</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:_______________________</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>tm2333683d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: right; width: 33%">&nbsp;</TD>
  <TD STYLE="text-align: center; width: 34%"><IMG SRC="tm2333683d1_ex5-1img001.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="text-align: right; width: 33%">919 Third Avenue <BR>
New York, NY 10022<BR>
212 935 3000 <BR>
mintz.com</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December 26, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">200 Connell Drive, Suite 1500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Berkeley Heights, NJ 07922</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have acted
as counsel to Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), <FONT STYLE="background-color: white">in
connection with (i) the issuance of an aggregate of 168,500 shares (the &ldquo;Shares&rdquo;) of common stock, par value $0.001 per share,
of the Company (&ldquo;<B><I>Common Stock</I></B>&rdquo;), (ii) pre-funded warrants (the &ldquo;<B><I>Pre-Funded Warrants</I></B>&rdquo;)
to purchase up to 219,700 shares of Common Stock, and (iii) up to 219,700 shares of Common Stock issuable upon exercise of the Pre-Funded
Warrants (the &ldquo;<B><I>Pre-funded Warrant Shares</I></B>&rdquo; and, together with the Shares and the Pre-Funded Warrants, the &ldquo;<B><I>Securities</I></B>&rdquo;).
The Securities are being offered and sold pursuant to the Registration Statement on&nbsp;Form S-3, including a base prospectus&nbsp;(File
No. </FONT>333-274328<FONT STYLE="background-color: white">) (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;), filed by the Company
with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) under the Securities Act of 1933, as amended
(the &ldquo;<B><I>Act</I></B>&rdquo;), which became effective on September 13, 2023, as supplemented by the&nbsp;prospectus supplement&nbsp;filed
with the Commission pursuant to Rule 424(b) under the Act (the base prospectus included in the Registration Statement and the prospectus
supplement filed with the Commission pursuant to Rule 424(b) under the Act being collectively referred to herein as the &ldquo;<B><I>Prospectus</I></B>&rdquo;)</FONT></FONT>
<FONT STYLE="background-color: white">and a Securities Purchase Agreement, dated as of December 21, 2023, among the Company and the purchasers
named therein (the &ldquo;<B><I>Purchase Agreement</I></B>&rdquo;). This opinion is being furnished in connection with the requirements
of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the
Registration Statement or related Prospectus, other than as expressly stated herein with respect to the issue of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with this opinion, we have examined and relied upon:
(A)&nbsp;the Registration Statement, (B) the Prospectus, (C)&nbsp;the Company&rsquo;s Amended and Restated Certificate of Incorporation,
as amended, and Amended and Restated Bylaws, as amended, (D) the Purchase Agreement and (E)&nbsp;the originals or copies certified to
our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate
to enable us to render the opinion expressed below. As to certain factual matters, we have relied upon a certificate of an officer of
the Company and have not independently verified such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In rendering this opinion, we have assumed the genuineness and authenticity
of all signatures on signed documents; the authenticity of all documents submitted to us as originals; the conformity to originals of
all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials; and the due
authorization, execution and delivery of all documents where due authorization, execution and delivery are a prerequisite to the effectiveness
thereof (except we have not made such assumption with respect to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our opinion herein is expressed solely with respect to the General
Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter
hereof and no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 7pt 0in 0in; border-top: Black 0.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps; text-transform: uppercase">Boston&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Los
Angeles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New York&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;San Diego&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;San
Francisco&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;toronto&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Washington</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">MINTZ, LEVIN,
COHN, FERRIS, GLOVSKY AND POPEO, P.C.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based upon the foregoing, and subject to the limitations set forth
below, we are of the opinion that (i) the Shares, when sold and issued in accordance with the Purchase Agreement and in the manner contemplated
by the Registration Statement and the Prospectus and Prospectus Supplement, will be validly issued, fully paid and nonassessable, (ii)
the Pre-Funded Warrants, when duly executed by the Company and delivered to the purchasers thereof against payment therefor as contemplated
in the Purchase Agreement, the Registration Statement and the Prospectus and Prospectus Supplement, will be valid and binding obligations
of the Company enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and other laws of general applicability relating to or affecting creditors&rsquo; rights and to general equity
principles; and (iii) the Warrant Shares, when issued and paid for in accordance with the terms of the Pre-Funded Warrants, will be validly
issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">This letter speaks only at and
as of its date and is based solely on the facts and circumstances known to us at and as of such date. We assume no obligation to revise
or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in fact or law
that may hereafter occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the reference to our firm under the caption &ldquo;Legal
Matters&rdquo; in the Prospectus included in the Registration Statement and to the filing of this opinion as an exhibit to the Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">/s/ Mintz, Levin, Cohn, Ferris, Glovsky &amp; Popeo, P.C.</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MINTZ, LEVIN, COHN, FERRIS, GLOVSKY &amp; POPEO, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 7pt 0in 0in; border-top: Black 0.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Boston&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;London&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Los
Angeles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New York&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;San Diego&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;San
Francisco&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Washington</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">MINTZ, LEVIN,
COHN, FERRIS, GLOVSKY AND POPEO, P.C.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>tm2333683d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLACEMENT AGENCY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 312.75pt">December&nbsp;21, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladenburg Thalmann&nbsp;&amp; Co. Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">640 Fifth Avenue, 4th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Introduction</B></FONT>.
Subject to the terms and conditions herein (this &ldquo;<U>Agreement</U>&rdquo;), Cyclacel Pharmaceuticals,&nbsp;Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), hereby agrees to sell up to an aggregate of $1,286,663.30 of securities of the Company, including,
168,500 registered shares (the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s common stock, $0.001 par value per share (the &ldquo;<U>Common
Stock</U>&rdquo;), registered Pre-Funded Common Stock purchase warrants to purchase up to an aggregate of 219,700 shares of Common Stock
(the &ldquo;<U>Registered Pre-Funded Warrants</U>&rdquo;) and unregistered Common Stock Warrants to purchase up to an aggregate of 388,200
shares of Common Stock (the &ldquo;<U>PIPE Warrants</U>&rdquo;, together with the Registered Pre-Funded Warrants, the &ldquo;<U>Warrants</U>&rdquo;
and the shares of Common Stock issuable upon exercise of the Warrants, the &ldquo;<U>Warrant Shares</U>&rdquo;) (the Shares, the Warrants
and Warrant Shares, collectively, the &ldquo;<U>Securities</U>&rdquo;) directly to one or more investors (each, an &ldquo;<U>Investor</U>&rdquo;
and, collectively, the &ldquo;<U>Investors</U>&rdquo;) through Ladenburg Thalmann&nbsp;&amp; Co. Inc. (the &ldquo;<U>Placement Agent</U>&rdquo;)
as placement agent. The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined
below), including, without limitation, a securities purchase agreement(s)&nbsp;(the &ldquo;<U>Purchase Agreement</U>&rdquo;), shall be
collectively referred to herein as the &ldquo;<U>Transaction Documents</U>.&rdquo; The Placement Agent may retain other brokers or dealers
to act as sub-agents or selected-dealers on its behalf in connection with the Offering (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company hereby confirms
its agreement with the Placement Agent as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;1.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Agreement
to Act as Placement Agent</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>On
the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms and conditions
of this Agreement, the Placement Agent shall be the exclusive placement agent in connection with the offering and sale by the Company
of the Shares, Registered Prefunded Warrants and Warrant Shares issuable upon exercise of the Registered Prefunded Warrants pursuant to
the Company&rsquo;s registration statement on Form&nbsp;S-3 (File No.&nbsp;333-274328) (including the exhibits thereto filed at such time,
and as may be amended from time to time, the &ldquo;<U>Registration Statement</U>&rdquo;) (such offering, the &ldquo;<U>Registered Offering</U>&rdquo;)
and a concurrent private placement of the PIPE Warrants (such private placement, the &ldquo;<U>Private Placement</U>&rdquo; and, together
with the Registered Offering, the &ldquo;<U>Offering</U>&rdquo;) with the terms of the Offering to be subject to market conditions and
negotiations between the Company, the Placement Agent and the prospective Investors. The Placement Agent will act on a reasonable best
efforts basis and the Company agrees and acknowledges that there is no guarantee of the successful placement of the Securities, or any
portion thereof, in the prospective Offering. Under no circumstances will the Placement Agent or any of its &ldquo;Affiliates&rdquo; (as
defined below) be obligated to underwrite or purchase any of the Securities for its own account or otherwise provide any financing. The
Placement Agent shall act solely as the Company&rsquo;s agent and not as principal. The Placement Agent shall have no authority to bind
the Company with respect to any prospective offer to purchase Securities and the Company shall have the sole right to accept offers to
purchase Securities and may reject any such offer, in whole or in part. Subject to the terms and conditions hereof, payment of the purchase
price for, and delivery of, the Securities shall be made at one or more closings (each a &ldquo;<U>Closing</U>&rdquo; and the applicable
date on which each Closing occurs, a &ldquo;<U>Closing Date</U>&rdquo;). As compensation for services rendered in connection with the
completion of each Closing, on each such Closing Date, the Company shall pay to the Placement Agent the fees and expenses set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>A
cash fee equal to 8.0% of the gross proceeds received by the Company from the sale of the Securities in each such Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company also agrees to reimburse Placement Agent&rsquo;s expenses up to an aggregate of $85,000 (with supporting invoices or receipts),
which shall be payable immediately upon the Closing of the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Such
number of Common Stock purchase warrants (the &ldquo;<U>Placement Agent Warrants</U>&rdquo;) to Placement Agent or its designees at each
Closing to purchase shares of Common Stock equal to 6.0% of the aggregate number of Shares and Unregistered Pre-Funded Warrants sold
in such Closing. The Placement Agent Warrants shall have substantially the same terms as the PIPE Warrants issued to the Investors in
the Offering except that the exercise price shall be <B>$4.14375</B> per share and shall have an expiration date of 5 years from the
commencement of sales of the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
term of the Placement Agent&rsquo;s exclusive engagement will be as provided in Section&nbsp;2 of that certain Investment Banking Agreement
dated October&nbsp;30, 2023 between the Company and the Placement Agent (the &ldquo;<U>Investment Banking Agreement</U>&rdquo;). Notwithstanding
anything to the contrary contained herein, the provisions concerning confidentiality, indemnification and contribution contained herein
and the Company&rsquo;s obligations contained in the indemnification provisions will survive any expiration or termination of this Agreement,
and the Company&rsquo;s obligation to pay fees actually earned and payable and to reimburse expenses actually incurred and reimbursable
pursuant to Section&nbsp;1 hereof and which are permitted to be reimbursed under FINRA Rule&nbsp;5110(f)(2)(D)(i), will survive any expiration
or termination of this Agreement. Nothing in this Agreement shall be construed to limit the ability of the Placement Agent or its Affiliates
to pursue, investigate, analyze, invest in, or engage in investment banking, financial advisory or any other business relationship with
Persons (as defined below) other than the Company. As used herein (i)&nbsp;&ldquo;Persons&rdquo; means an individual or corporation,
partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government
(or an agency or subdivision thereof) or other entity of any kind and (ii)&nbsp;&ldquo;Affiliate&rdquo; means any Person that, directly
or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms
are used in and construed under Rule&nbsp;405 under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;2.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Representations,
Warranties and Covenants of the Company</B>. The Company hereby represents, warrants and covenants to the Placement Agent as of the date
hereof, and as of each Closing Date, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Securities
Law Filings</U>. The Company has filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) the Registration
Statement under the Securities Act, which was filed on September&nbsp;1, 2023 and declared effective on September&nbsp;13, 2023, for the
registration of the Shares, Registered Prefunded Warrants and Warrant Shares underlying the Registered Prefunded Warrants under the Securities
Act. Following the determination of pricing among the Company and the prospective Investors introduced to the Company by the Placement
Agent, the Company will file with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act, and the rules&nbsp;and regulations
(the &ldquo;<U>Rules&nbsp;and Regulations</U>&rdquo;) of the Commission promulgated thereunder, a prospectus supplement relating to the
placement of the Shares, its pricing and the plan of distribution thereof and will advise the Placement Agent of all further information
(financial and other) with respect to the Company required to be set forth therein. Such prospectus in the form in which it appears in
the Registration Statement at the time of effectiveness, together with any preliminary prospectus supplement relating to the Offering,
if any (the &ldquo;<U>Preliminary Prospectus Supplement</U>&rdquo;) is hereinafter called the &ldquo;<U>Base Prospectus</U>&rdquo;; and
the final prospectus supplement, in the form in which it will be filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;(including
the Base Prospectus as it may be amended or supplemented) is hereinafter called the &ldquo;<U>Final Prospectus Supplement</U>.&rdquo;
Any reference in this Agreement to the Registration Statement, the Base Prospectus, the Preliminary Prospectus Supplement, if any or the
Final Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference therein (the &ldquo;<U>Incorporated
Documents</U>&rdquo;), if any, which were or are filed under the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;),
at any given time, as the case may be; and any reference in this Agreement to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or
 &ldquo;supplement&rdquo; with respect to the Registration Statement, the Base Prospectus, the Preliminary Prospectus Supplement or the
Final Prospectus Supplement shall be deemed to refer to and include the filing of any document under the Exchange Act after the date of
this Agreement, or the issue date of the Base Prospectus, the Preliminary Prospectus Supplement or the Final Prospectus Supplement, as
the case may be, deemed to be incorporated therein by reference. All references in this Agreement to financial statements and schedules
and other information which is &ldquo;contained,&rdquo; &ldquo;included,&rdquo; &ldquo;described,&rdquo; &ldquo;referenced,&rdquo; &ldquo;set
forth&rdquo; or &ldquo;stated&rdquo; in the Registration Statement, the Base Prospectus, the Preliminary Prospectus Supplement or the
Final Prospectus Supplement (and all other references of like import) shall be deemed to mean and include all such financial statements
and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Base Prospectus,
the Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be. As used in this paragraph and elsewhere
in this Agreement, &ldquo;<U>Time of Sale Disclosure Package</U>&rdquo; means the Base Prospectus, any preliminary prospectus supplement,
the Final Prospectus Supplement any securities purchase agreement between the Company and the Investors, and any issuer free writing prospectus
as defined in Rule&nbsp;433 of the Act (each, an &ldquo;<U>Issuer Free Writing Prospectus</U>&rdquo;), if any, that the parties hereto
shall hereafter expressly agree in writing to treat as part of the Time of Sale Disclosure Package. The term &ldquo;<U>any Prospectus
Supplement</U>&rdquo; shall mean, as the context requires, the Base Prospectus, the Final Prospectus Supplement, and any supplement to
either thereof. The Company has not received any notice that the Commission has issued or intends to issue a stop order suspending the
effectiveness of the Registration Statement or the use of the Base Prospectus or any Prospectus Supplement or intends to commence a proceeding
for any such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Assurances</U>.
The Registration Statement, as amended, (and any further documents to be filed with the Commission) contains all exhibits and schedules
as required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, at the time it became
effective, complied in all material respects with the Securities Act and the applicable Rules&nbsp;and Regulations and did not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading. The Base Prospectus, and the Prospectus Supplement, each as of its respective date, comply or will comply in all
material respects with the Securities Act and the applicable Rules&nbsp;and Regulations. Each of the Base Prospectus and the Prospectus
Supplement, as amended or supplemented, did not and will not contain as of the date thereof any untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance
upon and in conformity with information furnished in writing to the Company by the Placement Agent expressly for use therein. The Incorporated
Documents, when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act and the
applicable Rules&nbsp;and Regulations promulgated thereunder, and none of such documents, when they were filed with the Commission, contained
any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein (with respect to
Incorporated Documents incorporated by reference in the Base Prospectus or Prospectus Supplement), in light of the circumstances under
which they were made not misleading. No post-effective amendment to the Registration Statement reflecting any facts or events arising
after the date thereof which represent, individually or in the aggregate, a fundamental change in the information set forth therein is
required to be filed with the Commission. Except for applicable Transaction Documents, there are no documents required to be filed with
the Commission in connection with the transaction contemplated hereby that (x)&nbsp;have not been filed as required pursuant to the Securities
Act or (y)&nbsp;will not be filed within the requisite time period. Except for the Transaction Documents, there are no contracts or other
documents required to be described in the Base Prospectus or Prospectus Supplement, or to be filed as exhibits or schedules to the Registration
Statement, which have not been described or filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Offering
Materials</U>. Neither the Company nor any of its directors and officers has distributed and none of them will distribute, prior to each
Closing Date, any offering material in connection with the offering and sale of the Securities other than the Base Prospectus, the Prospectus
Supplement, the Registration Statement, copies of the documents incorporated by reference therein and any other materials permitted by
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents to which it is a party by the
Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action
on the part of the Company and no further action is required by the Company, the Company&rsquo;s Board of Directors or an authorized committee
thereof (the &ldquo;<U>Board of Directors</U>&rdquo;) or the Company&rsquo;s stockholders, if necessary, in connection therewith other
than in connection with the Required Approvals (as defined in the Purchase Agreement). This Agreement has been duly executed by the Company
and, when delivered in accordance with the terms hereof, assuming due authorization, execution and delivery by the Placement Agent, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)&nbsp;as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by
applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it
is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do
not (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s or any subsidiary&rsquo;s certificate or articles of incorporation,
bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice
or lapse of time or both would become a default) under, result in the creation of any Lien (as defined in the Purchase Agreement) (other
than as may be imposed by applicable state and federal securities laws and regulations with respect to the Warrants and Warrant Shares)
upon any of the properties or assets of the Company or any subsidiary, or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or subsidiary debt or otherwise) or other understanding to which the Company or any subsidiary is a party or by which any property
or asset of the Company or any subsidiary is bound or affected, or (iii)&nbsp;subject to the Required Approvals, conflict with or result
in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company or a subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and (iii), such as could
not have or reasonably be expected to result in a Material Adverse Effect (as defined in the Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Certificates</U>.
Any certificate signed by an officer of the Company and delivered to the&nbsp;Placement Agent or to counsel for the&nbsp;Placement Agent
shall be deemed to be a representation and warranty by the Company to&nbsp;the Placement Agent as to the matters set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Reliance</U>.
The Company acknowledges that the&nbsp;Placement Agent will rely upon the accuracy and truthfulness of the foregoing representations and
warranties and hereby consents to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Forward-Looking
Statements</U>. No forward-looking statements (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Exchange Act) contained in the Registration Statement, the Base Prospectus or the Prospectus Supplement has been made or reaffirmed without
a reasonable basis or has been disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Statistical
or Market-Related Data</U>. Any statistical, industry-related and market-related data included or incorporated by reference in the Registration
Statement, the Base Prospectus and the Prospectus Supplement, are based on or derived from sources that the Company reasonably and in
good faith believes to be reliable and accurate, an such data agree with the sources form which they are derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>FINRA
Affiliations</U>. There are no affiliations with any FINRA member firm that is participating in the Registered Offering among the Company&rsquo;s
officers or directors or, to the knowledge of the Company, any five percent (5%) or greater stockholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Representations
and Warranties Incorporated by Reference</U>. Each of the representations, warranties and covenants (together with any related disclosure
schedules thereto) made by the Company to the Investors in the Purchase Agreement is hereby incorporated herein by reference (as though
fully restated herein) and is hereby made to, and in favor of, the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;3.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Delivery
and Payment</B>. Each Closing shall occur at the offices of Ellenoff Grossman&nbsp;&amp; Schole LLP, 1345 Avenue of the Americas, New
York, New York 10105 (&ldquo;<U>Placement Agent Counsel</U>&rdquo;) (or at such other place as shall be agreed upon by the Placement Agent
and the Company). Subject to the terms and conditions hereof, at each Closing, payment of the purchase price for the Securities sold on
such Closing Date shall be made by Federal Funds wire transfer, against delivery of such Securities, and such Securities shall be registered
in such name or names and shall be in such denominations, as the Placement Agent may request at least one business day before the time
of purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deliveries of the documents
with respect to the purchase of the Securities, if any, shall be made at the offices of Placement Agent Counsel. All actions taken at
a Closing shall be deemed to have occurred simultaneously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;4.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Covenants
and Agreements of the Company</B>. The Company further covenants and agrees with the Placement Agent as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Registration
Statement Matters</U>. The Company will advise the Placement Agent promptly after it receives notice thereof of the time when any amendment
to the Registration Statement has been filed or becomes effective or any supplement to any Prospectus Supplement or any amended Prospectus
Supplement has been filed and will furnish the Placement Agent with copies thereof. The Company will file promptly all reports and any
definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 14
or 15(d)&nbsp;of the Exchange Act subsequent to the date of any Prospectus Supplement and for so long as the delivery of a prospectus
is required in connection with the Offering. The Company will advise the Placement Agent, promptly after it receives notice thereof (i)&nbsp;of
any request by the Commission to amend the Registration Statement or to amend or supplement any Prospectus Supplement or for additional
information, and (ii)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement
or any post-effective amendment thereto or any order directed at any Incorporated Document, if any, or any amendment or supplement thereto
or any order preventing or suspending the use of the Base Prospectus or any Prospectus Supplement or any amendment or supplement thereto
or any post-effective amendment to the Registration Statement, of the suspension of the qualification of the Securities for offering or
sale in any jurisdiction, of the institution or threatened institution of any proceeding for any such purpose, or of any request by the
Commission for the amending or supplementing of the Registration Statement or a Prospectus Supplement or for additional information. The
Company shall use its best efforts to prevent the issuance of any such stop order or prevention or suspension of such use.&nbsp; If the
Commission shall enter any such stop order or order or notice of prevention or suspension at any time, the Company will use its best efforts
to obtain the lifting of such order at the earliest possible moment, or will file a new registration statement and use its best efforts
to have such new registration statement declared effective as soon as practicable.&nbsp; Additionally, the Company agrees that in connection
with the Offering, it shall comply with the provisions of Rules&nbsp;424(b), 430A, 430B and 430C, as applicable, under the Securities
Act, including with respect to the timely filing of documents thereunder, and will use its reasonable efforts to confirm that any filings
made by the Company under such Rule&nbsp;424(b)&nbsp;are received in a timely manner by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Blue
Sky Compliance</U>. The Company will cooperate with the Placement Agent and the Investors in endeavoring to qualify the Securities for
sale under the securities laws of such jurisdictions (United States and foreign) as the Placement Agent and the Investors may reasonably
request and will make such applications, file such documents, and furnish such information as may be reasonably required for that purpose,
provided the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any
jurisdiction where it is not now so qualified or required to file such a consent, and provided further that the Company shall not be required
to produce any new disclosure document other than a Prospectus Supplement. The Company will, from time to time, prepare and file such
statements, reports and other documents as are or may be required to continue such qualifications in effect for so long a period as the
Placement Agent may reasonably request for distribution of the Securities. The Company will advise the Placement Agent promptly of the
suspension of the qualification or registration of (or any such exemption relating to) the Securities for offering, sale or trading in
any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending
such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest
possible moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Amendments
and Supplements to a Prospectus Supplement and Other Matters</U>. The Company will comply with the Securities Act and the Exchange Act,
and the rules&nbsp;and regulations of the Commission thereunder, so as to permit the completion of the distribution of the Securities
as contemplated in this Agreement, the Incorporated Documents and any Prospectus Supplement. If during the period in which a prospectus
is required by law to be delivered in connection with the distribution of Securities contemplated by the Incorporated Documents or any
Prospectus Supplement (the &ldquo;<U>Prospectus Delivery Period</U>&rdquo;), any event shall occur as a result of which, in the judgment
of the Company or in the opinion of the Placement Agent or counsel for the Placement Agent, it becomes necessary to amend or supplement
the Incorporated Documents or any Prospectus Supplement in order to make the statements therein, in the light of the circumstances under
which they were made, as the case may be, not misleading, or if it is necessary at any time to amend or supplement the Incorporated Documents
or any Prospectus Supplement or to file under the Exchange Act any Incorporated Document to comply with any law, the Company will promptly
prepare and file with the Commission, and furnish at its own expense to the Placement Agent and to dealers, an appropriate amendment to
the Registration Statement or supplement to the Registration Statement, the Incorporated Documents or any Prospectus Supplement that is
necessary in order to make the statements in the Incorporated Documents and any Prospectus Supplement as so amended or supplemented, in
the light of the circumstances under which they were made, as the case may be, not misleading, or so that the Registration Statement,
the Incorporated Documents or any Prospectus Supplement, as so amended or supplemented, will comply with law. Before amending the Registration
Statement or supplementing the Incorporated Documents or any Prospectus Supplement in connection with the Offering, the Company will furnish
the Placement Agent with a copy of such proposed amendment or supplement and will not file any such amendment or supplement to which the
Placement Agent reasonably objects; provided, however, that the Company may file any report determined by the Company to be required to
be filed pursuant to the Securities Act or the Exchange Act or the rules&nbsp;and regulations promulgated thereunder within the time period
required for such filing irrespective of any such objections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Copies
of any Amendments and Supplements to a Prospectus Supplement</U>. The Company will furnish the Placement Agent, without charge, during
the period beginning on the date hereof and ending on the later of the last Closing Date of the Offering, as many copies of the Incorporated
Documents and any Prospectus Supplement and any amendments and supplements thereto (including any Incorporated Documents, if any) as the
Placement Agent may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Free
Writing Prospectus</U>. The Company covenants that it will not, unless it obtains the prior written consent of the Placement Agent, make
any offer relating to the Securities that would constitute a Company Free Writing Prospectus or that would otherwise constitute a &ldquo;<U>free
writing prospectus</U>&rdquo; (as defined in Rule&nbsp;405 of the Securities Act) required to be filed by the Company with the Commission
or retained by the Company under Rule&nbsp;433 of the Securities Act. In the event that the Placement Agent expressly consents in writing
to any such free writing prospectus (a &ldquo;<U>Permitted Free Writing Prospectus</U>&rdquo;), the Company covenants that it shall (i)&nbsp;treat
each Permitted Free Writing Prospectus as an Company Free Writing Prospectus, and (ii)&nbsp;comply with the requirements of Rule&nbsp;164
and 433 of the Securities Act applicable to such Permitted Free Writing Prospectus, including in respect of timely filing with the Commission,
legending and record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Transfer
Agent</U>. The Company will maintain, at its expense, a registrar and transfer agent for the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Periodic
Reporting Obligations</U>. During the Prospectus Delivery Period, the Company will duly file, on a timely basis, with the Commission and
the Trading Market all reports and documents required to be filed under the Exchange Act within the time periods and in the manner required
by the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Additional
Documents</U>. The Company will enter into any subscription, purchase or other customary agreements as the Placement Agent or the Investors
deem necessary or appropriate to consummate the Offering, all of which will be in form and substance reasonably acceptable to the Placement
Agent and the Investors. The Company agrees that the Placement Agent may rely upon, and each is a third party beneficiary of, the representations
and warranties, and applicable covenants, set forth in any such purchase, subscription or other agreement with Investors in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Manipulation of Price</U><I>.&nbsp; </I>The Company will not take, directly or indirectly, any action designed to cause or result in,
or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any securities
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Acknowledgment</U>.
The Company acknowledges that any advice given by the Placement Agent to the Company is solely for the benefit and use of the Board of
Directors of the Company and may not be used, reproduced, disseminated, quoted or referred to, without the Placement Agent&rsquo;s prior
written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Announcement
of Offering</U>. The Company acknowledges and agrees that the Placement Agent may, subsequent to the Closing, make public its involvement
with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Reliance
on Others</U>. The Company confirms that it will rely on its own counsel and accountants for legal and accounting advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Research
Matters</U><FONT STYLE="font-variant: small-caps">.</FONT> By entering into this Agreement, the Placement Agent does not provide any promise,
either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby acknowledges and agrees
that the Placement Agent&rsquo;s selection as a placement agent for the Offering was in no way conditioned, explicitly or implicitly,
on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule&nbsp;2711(e), the parties
acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating or a specific
price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt of business or
compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;5.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Conditions
of the Obligations of the Placement Agent</B>. The obligations of the Placement Agent hereunder shall be subject to the accuracy of the
representations and warranties on the part of the Company set forth in Section&nbsp;2 hereof, in each case as of the date hereof and as
of each Closing Date as though then made, to the timely performance by each of the Company of its covenants and other obligations hereunder
on and as of such dates, and to each of the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliance
with Registration Requirements; No Stop Order; No Objection from the FINRA.</U> Each Prospectus Supplement (in accordance with Rule&nbsp;424(b))
and &ldquo;<U>free writing prospectus</U>&rdquo; (as defined in Rule&nbsp;405 of the Securities Act), if any, shall have been duly filed
with the Commission, as appropriate; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall
have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no order preventing or
suspending the use of any Prospectus Supplement shall have been issued and no proceeding for that purpose shall have been initiated or,
to the Company&rsquo;s knowledge, threatened by the Commission; no order having the effect of ceasing or suspending the distribution of
the Securities or any other securities of the Company shall have been issued by any securities commission, securities regulatory authority
or stock exchange and no proceedings for that purpose shall have been instituted or shall be pending or, to the knowledge of the Company,
contemplated by any securities commission, securities regulatory authority or stock exchange; all requests for additional information
on the part of the Commission shall have been complied with; and the FINRA shall have raised no objection to the fairness and reasonableness
of the placement terms and arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Corporate
Proceedings</U>. All corporate proceedings and other legal matters in connection with this Agreement, the Registration Statement and each
Prospectus Supplement, and the registration, sale and delivery of the Securities, shall have been completed or resolved in a manner reasonably
satisfactory to the Placement Agent&rsquo;s counsel, and such counsel shall have been furnished with such papers and information as it
may reasonably have requested to enable such counsel to pass upon the matters referred to in this Section&nbsp;5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Material Adverse Effect</U>. Subsequent to the execution and delivery of this Agreement and prior to each Closing Date, in the Placement
Agent&rsquo;s sole judgment after consultation with the Company, there shall not have occurred any Material Adverse Effect (as defined
in the Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Opinion
of Counsel for the Company</U>. The Placement Agent shall have received on each Closing Date the favorable opinion of legal counsel to
the Company, dated as of such Closing Date, including, without limitation, a negative assurance letter addressed to the Placement Agent
and in form and substance reasonably satisfactory to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Officers&rsquo;
Certificate</U>. The Placement Agent shall have received on each Closing Date a certificate of the Company, dated as of such Closing Date,
signed by the Chief Executive Officer and Chief Financial Officer of the Company, to the effect that, and the Placement Agent shall be
satisfied that, the signers of such certificate have reviewed the Registration Statement, the Incorporated Documents, any Prospectus Supplement,
and this Agreement and to the further effect that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
representations and warranties of the Company in this Agreement are true and correct, as if made on and as of such Closing Date, and the
Company has complied with all the agreements under this Agreement and satisfied all the conditions on its part to be performed or satisfied
at or prior to such Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>No
stop order suspending the effectiveness of the Registration Statement or the use of the Base Prospectus or any Prospectus Supplement has
been issued and no proceedings for that purpose have been instituted or are pending or, to the Company&rsquo;s knowledge, threatened under
the Securities Act; no order having the effect of ceasing or suspending the distribution of the Securities or any other securities of
the Company has been issued by any securities commission, securities regulatory authority or stock exchange in the United States and no
proceedings for that purpose have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities commission,
securities regulatory authority or stock exchange in the United States;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>When
the Registration Statement became effective, at the time of sale, and at all times subsequent thereto up to the delivery of such certificate,
the Registration Statement and the Incorporated Documents, if any, when such documents became effective or were filed with the Commission,
and any Prospectus Supplement, contained all material information required to be included therein by the Securities Act and the Exchange
Act and the applicable rules&nbsp;and regulations of the Commission thereunder, as the case may be, and in all material respects conformed
to the requirements of the Securities Act and the Exchange Act and the applicable rules&nbsp;and regulations of the Commission thereunder,
as the case may be, and the Registration Statement and the Incorporated Documents, if any, and any Prospectus Supplement, did not and
do not include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein, in the light of the circumstances under which they were made, not misleading (provided, however, that the
preceding representations and warranties contained in this paragraph (iii)&nbsp;shall not apply to any statements or omissions made in
reliance upon and in conformity with information furnished in writing to the Company by the Placement Agent expressly for use therein)
and, since the effective date of the Registration Statement, there has occurred no event required by the Securities Act and the rules&nbsp;and
regulations of the Commission thereunder to be set forth in the Incorporated Documents which has not been so set forth; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Subsequent
to the respective dates as of which information is given in the Registration Statement, the Incorporated Documents and any Prospectus
Supplement, there has not been: (a)&nbsp;any Material Adverse Effect; (b)&nbsp;any transaction that is material to the Company and the
subsidiaries taken as a whole, except transactions entered into in the ordinary course of business; (c)&nbsp;any obligation, direct or
contingent, that is material to the Company and the subsidiaries taken as a whole, incurred by the Company or any subsidiary, except obligations
incurred in the ordinary course of business; (d)&nbsp;any material change in the capital stock (except changes thereto resulting from
the exercise of outstanding stock options or warrants) or outstanding indebtedness of the Company or any subsidiary; (e)&nbsp;any dividend
or distribution of any kind declared, paid or made on the capital stock of the Company; or (f)&nbsp;any loss or damage (whether or not
insured) to the property of the Company or any subsidiary which has been sustained or will have been sustained which has a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Stock
Exchange Listing</U>. The Common Stock shall be registered under the Exchange Act and shall be listed on the Trading Market (as defined
in the Purchase Agreement), and the Company shall not have taken any action designed to terminate, or likely to have the effect of terminating,&nbsp;the
registration of the Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the Trading Market,
nor shall the Company have received any information suggesting that the Commission or the Trading Market is contemplating terminating
such registration or listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Additional
Documents</U>. On or before each Closing Date, the Placement Agent and counsel for the Placement Agent shall have received such information
and documents as they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of the Securities as
contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of
the conditions or agreements, herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any condition specified
in this Section&nbsp;5 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Placement Agent
by notice to the Company at any time on or prior to a Closing Date, which termination shall be without liability on the part of any party
to any other party, except that Section&nbsp;6 (Payment of Expenses), Section&nbsp;7 (Indemnification and Contribution) and Section&nbsp;8
(Representations and Indemnities to Survive Delivery) shall at all times be effective and shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;6.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Payment
of Expenses</B>. The Company agrees to pay all costs, fees and expenses incurred by the Company in connection with the performance of
its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (i)&nbsp;all expenses
incident to the issuance, delivery and qualification of the Securities (including all printing and engraving costs); (ii)&nbsp;all fees
and expenses of the registrar and transfer agent of the Common Stock; (iii)&nbsp;all necessary issue, transfer and other stamp taxes in
connection with the issuance and sale of the Securities; (iv)&nbsp;all fees and expenses of the Company&rsquo;s counsel, independent public
or certified public accountants and other advisors; (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing,
filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates
of experts), the Base Prospectus and each Prospectus Supplement, and all amendments and supplements thereto, and this Agreement; (vi)&nbsp;all
filing fees, reasonable attorneys&rsquo; fees and expenses incurred by the Company in connection with qualifying or registering (or obtaining
exemptions from the qualification or registration of) all or any part of the Securities for offer and sale under the state securities
or blue sky laws or the securities laws of any other country, and, if requested by the Placement Agent, preparing and printing a &ldquo;<U>Blue
Sky Survey</U>,&rdquo; an &ldquo;<U>International Blue Sky Survey</U>&rdquo; or other memorandum, and any supplements thereto, advising
the Placement Agent of such qualifications, registrations and exemptions; (vii)&nbsp;if applicable, the filing fees incident to the review
and approval by the FINRA of the Placement Agent&rsquo;s participation in the offering and distribution of the Securities; (viii)&nbsp;the
fees and expenses associated with including the Shares and the Warrant Shares on the Trading Market; and (ix)&nbsp;all other fees, costs
and expenses of the Company related to the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;7.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Indemnification.</B>
The Company agrees to indemnify the Placement Agent in accordance with the provisions of <U>Exhibit&nbsp;A</U> to the Investment Banking
Agreement, which is incorporated by reference herein and made a part hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;8.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Representations
and Indemnities to Survive Delivery</B>. The respective indemnities, agreements, representations, warranties and other statements of the
Company or any person controlling the Company, of its officers, and of the Placement Agent set forth in or made pursuant to this Agreement
will remain in full force and effect, regardless of any investigation made by or on behalf of the Placement Agent, the Company, or any
of its or their partners, officers or directors or any controlling person, as the case may be, and will survive delivery of and payment
for the Securities sold hereunder and any termination of this Agreement. A successor to a Placement Agent, or to the Company, its directors
or officers or any person controlling the Company, shall be entitled to the benefits of the indemnity, contribution and reimbursement
agreements contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;9.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Notices</B>.
All communications hereunder shall be in writing and shall be mailed, hand deliveredor e-mailed and confirmed to the parties hereto as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the Placement Agent to the address set forth
above, attention: General Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the Company, <FONT STYLE="background-color: white">200
Connell Drive, Suite&nbsp;1500</FONT>, Berkeley Heights, New Jersey 07922, attention: _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>With a copy to:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo
P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">919 Third Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">E-Mail: __________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attention: _________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any party hereto may change
the address for receipt of communications by giving written notice to the others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;10.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Successors</B>.
This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and
directors and controlling persons referred to in Section&nbsp;7 hereof, and to their respective successors, and personal representative,
and no other person will have any right or obligation hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;11.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Partial
Unenforceability</B>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the
validity or enforceability of any other section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement
is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor
changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;12.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Governing
Law Provisions</B>. This Agreement shall be deemed to have been made and delivered in New York City and both this Agreement and the transactions
contemplated hereby shall be governed as to validity, interpretation, construction, effect and in all other respects by the internal laws
of the State of New York, without regard to the conflict of laws principles thereof. Each of the Placement Agent and the Company: (i)&nbsp;agrees
that any legal suit, action or proceeding arising out of or relating to this Agreement and/or the transactions contemplated hereby shall
be instituted exclusively in New York Supreme Court, County of New York, or in the United States District Court for the Southern District
of New York, (ii)&nbsp;waives any objection which it may have or hereafter to the venue of any such suit, action or proceeding, and (iii)&nbsp;irrevocably
consents to the jurisdiction of the New York Supreme Court, County of New York, and the United States District Court for the Southern
District of New York in any such suit, action or proceeding. Each of the Placement Agent and the Company further agrees to accept and
acknowledge service of any and all process which may be served in any such suit, action or proceeding in the New York Supreme Court, County
of New York, or in the United States District Court for the Southern District of New York and agrees that service of process upon the
Company mailed by certified mail to the Company&rsquo;s address shall be deemed in every respect effective service of process upon the
Company, in any such suit, action or proceeding, and service of process upon the Placement Agent mailed by certified mail to the Placement
Agent&rsquo;s address shall be deemed in every respect effective service process upon the Placement Agent, in any such suit, action or
proceeding. Notwithstanding any provision of this Agreement to the contrary, the Company agrees that neither the Placement Agent nor its
affiliates, and the respective officers, directors, employees, agents and representatives of the Placement Agent, its affiliates and each
other person, if any, controlling the Placement Agent or any of its affiliates, shall have any liability (whether direct or indirect,
in contract or tort or otherwise) to the Company for or in connection with the engagement and transaction described herein except for
any such liability for losses, claims, damages or liabilities incurred by the Placement Agent that are finally judicially determined to
have resulted from fraud, the willful misconduct or gross negligence of such individuals or entities. If either party shall commence an
action or proceeding to enforce any provision of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed
by the other party for its reasonable attorney&rsquo;s fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;13.&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>General
Provisions</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">This
Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous
oral agreements, understandings and negotiations with respect to the subject matter hereof. Notwithstanding anything herein to the contrary,
the Investment Banking Agreement shall continue to be effective and the terms therein shall continue to survive and be enforceable by
the Placement Agent in accordance with its terms, including but not limited to, Section&nbsp;4(b)&nbsp;and Section&nbsp;5 therein. This
Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties
hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant
to benefit. Section&nbsp;headings herein are for the convenience of the parties only and shall not affect the construction or interpretation
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Company acknowledges that in connection with the offering of the Securities: (i)&nbsp;the Placement Agent has acted at arms length, are
not agents of, and owe no fiduciary duties to the Company or any other person, (ii)&nbsp;the Placement Agent owes the Company only those
duties and obligations set forth in this Agreement and (iii)&nbsp;the Placement Agent may have interests that differ from those of the
Company. The Company waives to the full extent permitted by applicable law any claims it may have against the Placement Agent arising
from an alleged breach of fiduciary duty in connection with the offering of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>The remainder of this page&nbsp;has been intentionally
left blank.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is in accordance
with your understanding of our agreement, please sign below whereupon this instrument, along with all counterparts hereof, shall become
a binding agreement in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>CYCLACEL PHARMACEUTICALS,&nbsp;INC.,</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">a Delaware corporation</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Spiro Rombotis</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Spiro Rombotis</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: President &amp; CEO</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing Placement Agency
Agreement is hereby confirmed and accepted as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LADENBURG THALMANN&nbsp;&amp; CO. INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Nicholas Stergis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Nicholas Stergis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Managing Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>tm2333683d1_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of December&nbsp;21, 2023, between Cyclacel Pharmaceuticals,&nbsp;Inc., a
Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages&nbsp;hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to (i)&nbsp;an effective registration statement under the Securities Act (as
defined below) as to the Shares and Prefunded Warrants and (ii)&nbsp;an exemption from the registration requirements of Section&nbsp;5
of the Securities Act contained in Section&nbsp;4(a)(2)&nbsp;thereof and/or Regulation D thereunder as to the Common Warrants, the Company
desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities
of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,&nbsp;IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&nbsp;I.</B></FONT><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section&nbsp;1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i)&nbsp;the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)&nbsp;the
Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second
(2<SUP>nd</SUP>) Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Warrants</U>&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section&nbsp;2.2(a)&nbsp;hereof, which Common Warrants shall be exercisable immediately at an exercise price equal to
$<B>3.19</B>, subject to adjustment therein and have a term of exercise equal to seven years, in the form of Exhibit&nbsp;A-1
attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C., with offices located at 919 Third Avenue, New York, NY 10022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i)&nbsp;if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m.&nbsp;(New York City
time) and before midnight (New York City time) on any Trading Day, 9:01 a.m.&nbsp;(New York City time) on the Trading Day immediately
following the date hereof, unless otherwise agreed by the Company and the Placement Agent, and (ii)&nbsp;if this Agreement is signed
between midnight (New York City time) and 9:00 a.m.&nbsp;(New York City time) on any Trading Day, no later than 9:01 a.m.&nbsp;(New York
City time) on the date hereof, unless otherwise agreed by the Company and the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman&nbsp;&amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a)&nbsp;shares of Common Stock or options, restricted stock units or other equity awards to
employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of
the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established
for such purpose for services rendered to the Company, (b)&nbsp;securities upon the exercise or exchange of or conversion of any Securities
issued hereunder, warrants to the Placement Agent in connection with the transactions pursuant to this Agreement and any securities upon
exercise of warrants to the Placement Agent and/or other securities exercisable or exchangeable for or convertible into shares of Common
Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this
Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities
(other than in connection with stock splits or combinations) or to extend the term of such securities, (c)&nbsp;securities issued pursuant
to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights that require or permit
the filing of any registration statement in connection therewith during the prohibition period in Section&nbsp;4.12(a)&nbsp;herein, and
provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, and (d)&nbsp;up to 10,000
shares of Common Stock and warrants to purchase up to 10,000 shares of Common Stock to officers or directors of the Company in a concurrent
private placement at a purchase price equal to &ldquo;market value&rdquo; in accordance with the rules&nbsp;of the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section&nbsp;3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals $<B>3.315</B>, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement, provided that the purchase price per
Prefunded Warrant shall be the Per Share Purchase Price minus $0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means Ladenburg Thalmann&nbsp;&amp; Co. Inc..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prefunded
Warrant</U>&rdquo; means, collectively, the Prefunded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section&nbsp;2.2(a)&nbsp;hereof, which Prefunded Warrants shall be exercisable immediately and shall expire when exercised in full,
in the form of <U>Exhibit&nbsp;A-2</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prefunded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Prefunded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule&nbsp;424(b)&nbsp;of the Securities Act that is filed
with the Commission and delivered by the Company to each Purchaser at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No.&nbsp;333-274328 which registers the sale of
the Shares, Prefunded Warrants and shares of Common Stock underlying the Prefunded Warrants to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Resale
Effective Date</U>&rdquo; means the date that a Resale Registration Statement registering the resale of all Warrant Shares underlying
the Common Warrants has been declared effective by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Resale
Registration Statement</U>&rdquo; means a registration statement meeting the requirements set forth in Section&nbsp;4.18 hereof and covering
the resale by the Purchasers of the Warrant Shares underlying the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;144</U>&rdquo;
means Rule&nbsp;144 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from
time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;424</U>&rdquo;
means Rule&nbsp;424 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from
time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule&nbsp;200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants and Prefunded Warrants purchased
hereunder as specified below such Purchaser&rsquo;s name on the signature page&nbsp;of this Agreement and next to the heading &ldquo;Subscription
Amount,&rdquo; in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise
price of the Prefunded Warrants, which amounts shall be paid as and when such Prefunded Warrants are exercised).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any significant subsidiary of the Company, as defined in Rule&nbsp;1.02 of Regulation S-X under the Securities Act, and shall,
where applicable, also include any direct or indirect significant subsidiary of the Company, as defined in Rule&nbsp;1.02 of Regulation
S-X under the Securities Act, formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, the Pink Market, OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, the Prefunded Warrants, all exhibits and schedules thereto and hereto and any
other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, LLC, the current transfer agent of the Company, with a mailing address of 6201, 15th Avenue,
Brooklyn, New York 11219, and an email address of LegalTeamUS@equiniti.com, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.12(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if the OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;)
or the OTCQX Best Market (&ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted
for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the Pink Open Market (&ldquo;<U>Pink Market</U>&rdquo;)
operated by OTC Markets,&nbsp;Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Warrants and Prefunded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&nbsp;II.</B></FONT><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally
and not jointly, agree to purchase, up to an aggregate of $<B>1,286,663.30</B> of Shares and Warrants; <U>provided</U>, <U>howeve</U>r,
that, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&rsquo;s Affiliates,
and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s Affiliates) would beneficially own in
excess of the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, in lieu of purchasing Shares such Purchaser
may elect to purchase Prefunded Warrants in lieu of Shares in such manner to result in the same aggregate purchase price being paid by
such Purchaser to the Company. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at the election of the Purchaser
at Closing, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities
on the Closing Date.. Each Purchaser&rsquo;s Subscription Amount for its Common Stock as set forth on the signature page&nbsp;hereto
executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee.
The Company shall deliver to each Purchaser its respective Shares and Warrants as determined pursuant to Section&nbsp;2.2(a), and the
Company and each Purchaser shall deliver the other items set forth in Section&nbsp;2.2 deliverable at the Closing. Upon satisfaction
of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the
Closing documentation. Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement
by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement
Period</U>&rdquo;), such Purchaser sells to any Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at
the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Purchaser shall, automatically hereunder (without any
additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such Pre-Settlement
Shares at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior
to the Company&rsquo;s receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that the Company hereby
acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during
the Pre-Settlement Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares
of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any. Unless otherwise
directed by the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;)
(i.e., on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by
the Transfer Agent directly to the account(s)&nbsp;at the Placement Agent identified by each Purchaser; upon receipt of such Shares,
the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made
by the Placement Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of
Exercise (as defined in the Prefunded Warrants) delivered on or prior to 12:00 p.m.&nbsp;(New York City time) on the Closing Date, which
may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver the Prefunded Warrant Shares
subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City time) on the Closing Date and the Closing Date shall be the Warrant Share
Delivery Date (as defined in the Prefunded Warrants) for purposes hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">a
legal opinion of Company Counsel, substantially in the form of <U>Exhibit&nbsp;B</U> attached hereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">subject
to the last sentence of Section&nbsp;2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions,
on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">subject
to the last sentence of Section&nbsp;2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent
to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
Shares equal to such Purchaser&rsquo;s Subscription Amount (or portion thereof with respect to a Purchaser of Prefunded Warrants pursuant
to Section&nbsp;2.1) divided by the Per Share Purchase Price, registered in the name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">a
Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of such Purchaser&rsquo;s
Subscription Amount divided by the Per Share Purchase Price, with an exercise price equal to $<B>3.19</B>, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">for
each Purchaser of a Prefunded Warrant pursuant to Section&nbsp;2.1, a Prefunded Warrant registered in the name of such Purchaser to purchase
up to a number of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to Prefunded Warrant
divided by the Per Share Purchase Price minus $0.001, with an exercise price equal to $0.001, subject to adjustment therein; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule&nbsp;172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, as applicable, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">such
Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company
or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing
Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on
the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which
case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in
all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b)&nbsp;of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein in which case they shall be accurate in all respects or, to the extent representations or warranties are qualified
by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
delivery by the Company of the items set forth in Section&nbsp;2.2(a)&nbsp;of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">there
shall have been no Material Adverse Effect with respect to the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&nbsp;III.</B></FONT><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part
hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section
of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsidiaries</U>.
All of the Subsidiaries of the Company are disclosed in the SEC Reports. The Company owns, directly or indirectly, all of the capital
stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital
stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe
for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction
Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority
to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary
is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i)&nbsp;a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii)&nbsp;a
material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company
and the Subsidiaries, taken as a whole, or (iii)&nbsp;a material adverse effect on the Company&rsquo;s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document (any of (i), (ii)&nbsp;or (iii), a &ldquo;<U>Material Adverse
Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke,
limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)&nbsp;as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)&nbsp;subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in
connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)&nbsp;the filings
required pursuant to Section&nbsp;4.4 of this Agreement, (ii)&nbsp;the filing with the Commission of the Prospectus Supplement, (iii)&nbsp;application(s)&nbsp;to
each applicable Trading Market for the listing of the Shares and Warrant Shares and Prefunded Warrant Shares for trading thereon in the
time and manner required thereby, and (iv)&nbsp;the filing of Form&nbsp;D with the Commission and such filings as are required to be
made under applicable state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.
The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free
and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of
shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement
in conformity with the requirements of the Securities Act, which became effective on&nbsp;September&nbsp;13, 2023 (the &ldquo;<U>Effective
Date</U>&rdquo;), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this
Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness
of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings
for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required
by the rules&nbsp;and regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule&nbsp;424(b). At the
time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the
Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at
the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all
material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading. The Company was at the time of the filing of the Registration Statement eligible to use Form&nbsp;S-3. The Company
is eligible to use Form&nbsp;S-3 under the Securities Act and it meets the transaction requirements with respect to the aggregate market
value of securities being sold pursuant to this offering and during the twelve (12) months prior to this offering, as set forth in General
Instruction I.B.6 of Form&nbsp;S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.
The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which <U>Schedule 3.1(g)</U>&nbsp;shall
also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof.
The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant
to the exercise of employee stock options under the Company&rsquo;s stock option plans, awards or vesting of awards under the Company&rsquo;s
stock or option plan, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans
and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic
report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right
to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities
and as set forth on <U>Schedule 3.1(g)</U>, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares
of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate
the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are
no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange
or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding
securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the
Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements
or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued,
fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding
shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval
or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There
are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which
the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>SEC
Reports; Financial Statements</U>. Except as set forth on Schedule 3.1(h), the Company has filed all reports, schedules, forms, statements
and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or
15(d)&nbsp;thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation
to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together
with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on
a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of
any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities
Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule&nbsp;144(i)&nbsp;under
the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules&nbsp;and regulations of the Commission with respect thereto as in effect at the time of filing.
Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent
basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the
notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all
material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results
of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end
audit adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports, except as disclosed in a subsequent SEC Report, (i)&nbsp;there has been no event, occurrence or development that has
had or that could reasonably be expected to result in a Material Adverse Effect, (ii)&nbsp;the Company has not incurred any liabilities
(contingent or otherwise) other than (A)&nbsp;trade payables and accrued expenses incurred in the ordinary course of business consistent
with past practice and (B)&nbsp;liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP
or disclosed in filings made with the Commission, (iii)&nbsp;the Company has not altered its method of accounting, (iv)&nbsp;the Company
has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any
agreements to purchase or redeem any shares of its capital stock and (v)&nbsp;the Company has not issued any equity securities to any
officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the
Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement
or as set forth on <U>Schedule 3.1(i)</U>, no event, liability, fact, circumstance, occurrence or development has occurred or exists
or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects,
properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities
laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the
date that this representation is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Litigation</U>.
Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending
or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth on <U>Schedule 3.1(j)</U>, (i)&nbsp;adversely affects or
challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii)&nbsp;could, if there
were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary,
nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal
or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not
pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the
Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed
by the Company or any Subsidiary under the Exchange Act or the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their
relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance</U>.
Neither the Company nor any Subsidiary: (i)&nbsp;is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company
or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit
agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not
such default or violation has been waived), (ii)&nbsp;is in violation of any judgment, decree or order of any court, arbitrator or other
governmental authority or (iii)&nbsp;is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority,
including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health
and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected
to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Environmental
Laws</U>.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The Company and its
Subsidiaries (i)&nbsp;are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human
health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating
to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or
wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes,
decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations,
issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii)&nbsp;have received all permits licenses
or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii)&nbsp;are in
compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii)&nbsp;and (iii), the failure
to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in
each case free and clear of all Liens, except for (i)&nbsp;Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii)&nbsp;Liens for the
payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment
of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)&nbsp;years from the date of this
Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within
the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge
of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any
of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any
Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transactions
With Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of the Company or
any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any
transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i)&nbsp;payment
of salary or consulting fees for services rendered, (ii)&nbsp;reimbursement for expenses incurred on behalf of the Company and (iii)&nbsp;other
employee benefits, including stock option agreements under any stock option plan of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the
Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules&nbsp;and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Except as disclosed in
the SEC Reports, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable
assurance that: (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv)&nbsp;the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange
Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures
to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules&nbsp;and forms. The Company&rsquo;s
certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as
of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation
Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying
officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since
the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange
Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control
over financial reporting of the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions are or will
be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this
Section&nbsp;that may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Registration
Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any
securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange Act,
and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as disclosed in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in
the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently
eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is
current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such
electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their
obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s
issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus
Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions
in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company
and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this
Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press
releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges
and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby
other than those specifically set forth in Section&nbsp;3.2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section&nbsp;3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of (i)&nbsp;the Securities Act which would require the registration
of the Warrants or Warrant Shares under the Securities Act, or (ii)&nbsp;any applicable shareholder approval provisions of any Trading
Market on which any of the securities of the Company are listed or designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i)&nbsp;the fair saleable value of the Company&rsquo;s assets exceeds the
amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii)&nbsp;the Company&rsquo;s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital
requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof,
and (iii)&nbsp;the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of
its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its
liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts
as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge
of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. The SEC Reports set forth as of the date hereof all outstanding secured
and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes
of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x)&nbsp;any liabilities for borrowed money or amounts owed in excess of $50,000
(other than trade accounts payable incurred in the ordinary course of business), (y)&nbsp;all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (z)&nbsp;the present value of any lease payments in excess of $50,000 due under
leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect, the Company and its Subsidiaries each (i)&nbsp;has made or filed all United States federal, state and local income and
all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)&nbsp;has
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii)&nbsp;has set aside on its books provision reasonably adequate for the payment of all material taxes
for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)&nbsp;made any unlawful payment
to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii)&nbsp;failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its
behalf of which the Company is aware) which is in violation of law, or (iv)&nbsp;violated in any material respect any provision of FCPA.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Accountants</U>.
The Company&rsquo;s accounting firm is RSM US LLP. To the knowledge and belief of the Company, such accounting firm (i)&nbsp;is a registered
public accounting firm as required by the Exchange Act and (ii)&nbsp;shall express its opinion with respect to the financial statements
to be included in the Company&rsquo;s Annual Report for the fiscal year ending December&nbsp;31, 2023.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Sections 3.2(f)&nbsp;and 4.14 hereof), it is understood and acknowledged by the Company that: (i)&nbsp;none of the Purchasers has
been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities
of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii)&nbsp;past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short
Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii)&nbsp;any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock, and (iv)&nbsp;each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party
in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y)&nbsp;one or more Purchasers may
engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during
the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z)&nbsp;such hedging
activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the
hedging activities are being conducted.&nbsp; The Company acknowledges that such aforementioned hedging activities do not constitute
a breach of any of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i)&nbsp;taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii)&nbsp;sold, bid for, purchased, or, paid any compensation for soliciting purchases of,
any of the Securities, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii)&nbsp;and (iii), compensation paid to the Placement Agent in connection
with the placement of the Securities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged, labeled,
tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical Product</U>&rdquo;),
such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance
with all applicable requirements under FDCA and similar laws, rules&nbsp;and regulations relating to registration, investigational use,
premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices,
product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would
not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any
lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or
any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication
from the FDA or any other governmental entity, which (i)&nbsp;contests the premarket clearance, licensure, registration, or approval
of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of
any Pharmaceutical Product, (ii)&nbsp;withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders
the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii)&nbsp;imposes a clinical hold
on any clinical investigation by the Company or any of its Subsidiaries, (iv)&nbsp;enjoins production at any facility of the Company
or any of its Subsidiaries, (v)&nbsp;enters or proposes to enter into a consent decree of permanent injunction with the Company or any
of its Subsidiaries, or (vi)&nbsp;otherwise alleges any violation of any laws, rules&nbsp;or regulations by the Company or any of its
Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and
operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules&nbsp;and
regulations of the FDA.&nbsp; The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or
use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern
as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i)&nbsp;in accordance
with the terms of the Company&rsquo;s stock option plan and (ii)&nbsp;with an exercise price at least equal to the fair market value
of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no
Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cybersecurity</U>.&nbsp;
To the Company&rsquo;s knowledge, (i)(x)&nbsp;there has been no security breach or other compromise of or relating to any of the Company&rsquo;s
or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its
respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology
(collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and
has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to
its IT Systems and Data; (ii)&nbsp;the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes
and all judgments, orders, rules&nbsp;and regulations of any court or arbitrator or governmental or regulatory authority, internal policies
and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and
Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material
Adverse Effect; (iii)&nbsp;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain
and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems
and Data; and (iv)&nbsp;the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry
standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Data Privacy Laws</U>. To the Company&rsquo;s knowledge, (i)&nbsp;the Company and the Subsidiaries are, and at all times during
the last three (3)&nbsp;years were, in compliance with all applicable state, federal and foreign data privacy and security laws and regulations,
including, without limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively,
 &ldquo;<U>Privacy Laws</U>&rdquo;); (ii)&nbsp;the Company and the Subsidiaries have in place, comply with, and take appropriate steps
reasonably designed to ensure compliance with their policies and procedures relating to data privacy and security and the collection,
storage, use, disclosure, handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii)&nbsp;the
Company provides accurate notice of its applicable Policies to its customers, employees, third party vendors and representatives as required
by the Privacy Laws; and (iv)&nbsp;applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy
practices relating to its subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices,
as required by Privacy Laws.&nbsp;&ldquo;<U>Personal Data</U>&rdquo; means (i)&nbsp;a natural person&rsquo;s name, street address, telephone
number, email address, photograph, social security number, bank information, or customer or account number; (ii)&nbsp;any information
which would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii)&nbsp;&ldquo;personal
data&rdquo; as defined by GDPR; and (iv)&nbsp;any other piece of information that allows the identification of such natural person, or
his or her family, or permits the collection or analysis of any identifiable data related to an identified person&rsquo;s health or sexual
orientation. (i)&nbsp;None of such disclosures made or contained in any of the Policies have been inaccurate, misleading, or deceptive
in violation of any Privacy Laws and (ii)&nbsp;the execution, delivery and performance of the Transaction Documents will not result in
a breach of any Privacy Laws or Policies.&nbsp; Neither the Company nor the Subsidiaries (i)&nbsp;to the knowledge of the Company, has
received written notice of any actual or potential liability of the Company or the Subsidiaries under, or actual or potential violation
by the Company or the Subsidiaries of, any of the Privacy Laws; (ii)&nbsp;is currently conducting or paying for, in whole or in part,
any investigation, remediation or other corrective action pursuant to any regulatory request or demand pursuant to any Privacy Law; or
(iii)&nbsp;is a party to any order, decree, or agreement by or with any court or arbitrator or governmental or regulatory authority that
imposed any obligation or liability under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of
1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules&nbsp;and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Private
Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section&nbsp;3.2, no registration
under the Securities Act is required for the offer and sale of the Warrants or the Warrant Shares by the Company to the Purchasers as
contemplated hereby.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Warrant or
Warrant Shares by any form of general solicitation or general advertising. The Company has offered the Warrants and Warrant Shares for
sale only to the Purchasers and certain other &ldquo;accredited investors&rdquo; within the meaning of Rule&nbsp;501 under the Securities
Act.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Disqualification Events</U>. With respect to the Warrant and Warrant Shares to be offered and sold hereunder in reliance on Rule&nbsp;506
under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other
officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding
voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule&nbsp;405 under the
Securities Act) connected with the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo;)
is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule&nbsp;506(d)(1)(i)&nbsp;to (viii)&nbsp;under the
Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;), except for a Disqualification Event covered by Rule&nbsp;506(d)(2)&nbsp;or
(d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event.
The Company has complied, to the extent applicable, with its disclosure obligations under Rule&nbsp;506(e), and has furnished to the
Purchasers a copy of any disclosures provided thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Other
Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that
has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
of Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i)&nbsp;any Disqualification
Event relating to any Issuer Covered Person and (ii)&nbsp;any event that would, with the passage of time, reasonably be expected to become
a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i)&nbsp;as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.
Such Purchaser understands that the Warrants and the Warrant Shares are &ldquo;restricted securities&rdquo; and have not been registered
under the Securities Act or any applicable state securities law and is acquiring such Securities as principal for his, her or its own
account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities
Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute
or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation
and warranty not limiting such Purchaser&rsquo;s right to sell such Securities pursuant to a registration statement or otherwise in compliance
with applicable federal and state securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Warrants, it will be an &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501(a)(1), (a)(2), (a)(3), (a)(7),
(a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded, (i)&nbsp;the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii)&nbsp;the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment.&nbsp; Such Purchaser acknowledges and agrees that
neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with
respect to the Securities nor is such information or advice necessary or desired.&nbsp; Neither the Placement Agent nor any Affiliate
has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may
have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it.&nbsp; In connection
with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial
advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms
of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the
case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other
portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to
other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors,
partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>General
Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at
any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company acknowledges and agrees that the representations contained in </FONT>this Section&nbsp;3.2 shall not modify, amend or affect
such Purchaser&rsquo;s right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations
and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection
with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of
doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing
shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&nbsp;IV.</B></FONT><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Removal
of Legends</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Common Warrants and Warrant Shares underlying the Common Warrants may only be disposed of in compliance with state and federal securities
laws. In connection with any transfer of Common Warrants or Warrant Shares underlying the Common Warrants other than pursuant to an effective
registration statement or Rule&nbsp;144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated
in Section&nbsp;4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the
transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the
Company, to the effect that such transfer does not require registration of such transferred Common Warrant under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Purchasers agree to the imprinting, so long as is required by this Section&nbsp;4.1, of a legend on any of the Common Warrants or Warrant
Shares underlying the Common Warrants in the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES
INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY&nbsp;NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND
IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY&nbsp;BE
PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT
IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a)&nbsp;UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The Company acknowledges
and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or
grant a security interest in some or all of the Common Warrants or Warrant Shares underlying the Common Warrants to a financial institution
that is an &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501(a)&nbsp;under the Securities Act and, if required under the
terms of such arrangement, such Purchaser may transfer pledged or secured Common Warrants or Warrant Shares underlying the Common Warrants
to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of
legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required
of such pledge. At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable documentation as a
pledgee or secured party of Common Warrants and Warrant Shares underlying the Common Warrants may reasonably request in connection with
a pledge or transfer of the Common Warrants or Warrant Shares underlying the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Certificates
evidencing the Warrant Shares underlying the Common Warrants shall not contain any legend (including the legend set forth in Section&nbsp;4.1(b)&nbsp;hereof):
(i)&nbsp;while a registration statement covering the resale of such security is effective under the Securities Act, or (ii)&nbsp;following
any sale of such Warrant Shares pursuant to Rule&nbsp;144 (assuming cashless exercise of the Warrants), or (iii)&nbsp;if such Warrant
Shares are eligible for sale under Rule&nbsp;144 (assuming cashless exercise of the Common Warrants), or (iv)&nbsp;if such legend is
not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the
staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser promptly
if required by the Transfer Agent to effect the removal of the legend hereunder, or if requested by a Purchaser, respectively. If all
or any portion of a Common Warrant is exercised at a time when there is an effective registration statement to cover the resale of the
Warrant Shares underlying the Common Warrants, or if such Warrant Shares may be sold under Rule&nbsp;144 (assuming cashless exercise
of the Common Warrants) or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the staff of the Commission) then such Warrant Shares shall be issued free of all legends,
provided that the Company and/or its counsel are provided with any representations or supporting documentation that they may reasonably
request. The Company agrees that following such time as such legend is no longer required under this Section&nbsp;4.1(c), the Company
will, no later than the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard
Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing
Warrant Shares, as applicable, issued with a restrictive legend (such date, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or
cause to be delivered to such Purchaser a certificate representing such shares that is free from all restrictive and other legends, provided
that the Company and/or its counsel are provided with any representations or supporting documentation that they may reasonably request.
The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer
set forth in this Section&nbsp;4. Warrant Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the
Purchaser by crediting the account of the Purchaser&rsquo;s prime broker with the Depository Trust Company System as directed by such
Purchaser. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of a certificate representing Warrant Shares issued with a restrictive legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i)&nbsp;as partial liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares (based on the VWAP of the Common Stock on the date such Securities are
submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section&nbsp;4.1(c), $10 per Trading
Day (increasing to $20 per Trading Day three (3)&nbsp;Trading Days after the Legend Removal Date) for each Trading Day after the Legend
Removal Date until such certificate is delivered without a legend and (ii)&nbsp;if the Company fails to (a)&nbsp;issue and deliver (or
cause to be delivered) to a Purchaser by the Legend Removal Date a certificate representing the Securities so delivered to the Company
by such Purchaser that is free from all restrictive and other legends and (b)&nbsp;if after the Legend Removal Date such Purchaser purchases
(in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or
any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the
number of shares of Common Stock, that such Purchaser anticipated receiving from the Company without any restrictive legend, then an
amount equal to the excess of such Purchaser&rsquo;s total purchase price (including customary brokerage commissions and other reasonable
out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including customary brokerage commissions and other reasonable
out-of-pocket expenses, if any) (the &ldquo;<U>Buy-In Price</U>&rdquo;) over the product of (A)&nbsp;such number of Warrant Shares that
the Company was required to deliver to such Purchaser by the Legend Removal Date multiplied by (B)&nbsp;the lowest closing sale price
of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such Purchaser to the Company of the
applicable Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this Section&nbsp;4.1(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Shares Prefunded Warrants, and Prefunded Warrant Shares shall be issued free of legends. If all or any portion of a Prefunded Warrant
is exercised at a time when there is an effective registration statement to cover the issuance or resale of the Prefunded Warrant Shares
or if the Prefunded Warrant is exercised via cashless exercise, the Prefunded Warrant Shares issued pursuant to any such exercise shall
be issued free of all legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement
registering the sale or resale of the Prefunded Warrant Shares) is not effective or is not otherwise available for the sale or resale
of the Prefunded Warrant Shares, the Company shall immediately notify the holders of the Prefunded Warrants in writing that such registration
statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again
and available for the sale or resale of the Prefunded Warrant Shares (it being understood and agreed that the foregoing shall not limit
the ability of the Company to issue, or any Purchaser to sell, any of the Prefunded Warrant Shares in compliance with applicable federal
and state securities laws). The Company shall use best efforts to keep a registration statement (including the Registration Statement)
registering the issuance or resale of the Prefunded Warrant Shares effective during the term of the Prefunded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Furnishing
of Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Until
the earlier of the time that (i)&nbsp;no Purchaser owns Securities or (ii)&nbsp;the Warrants have expired, the Company covenants to timely
file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company
after the date hereof pursuant to the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
any time during the period commencing from the six (6)&nbsp;month anniversary of the date hereof and ending at such time that all of
the Warrant Shares underlying the Common Warrants (assuming cashless exercise) may be sold without the requirement for the Company to
be in compliance with Rule&nbsp;144(c)(1)&nbsp;and otherwise without restriction or limitation pursuant to Rule&nbsp;144, if the Company
(i)&nbsp;shall fail for any reason to satisfy the current public information requirement under Rule&nbsp;144(c)&nbsp;or (ii)&nbsp;has
ever been an issuer described in Rule&nbsp;144(i)(1)(i)&nbsp;or becomes an issuer in the future, and the Company shall fail to satisfy
any condition set forth in Rule&nbsp;144(i)(2)&nbsp;(a &ldquo;<U>Public Information Failure</U>&rdquo;) then, in addition to such Purchaser&rsquo;s
other available remedies, the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason
of any such delay in or reduction of its ability to sell the Warrant Shares, an amount in cash equal to one percent (1.0%) of the aggregate
Exercise Price of such Purchaser&rsquo;s outstanding Common Warrants on the day of a Public Information Failure and on every thirtieth
(30<SUP>th</SUP>) day (pro rated for periods totaling less than thirty days) thereafter until the earlier of (a)&nbsp;the date such Public
Information Failure is cured and (b)&nbsp;such time that such public information is no longer required&nbsp; for the Purchasers to transfer
the Warrant Shares underlying the Common Warrants pursuant to Rule&nbsp;144.&nbsp; The payments to which a Purchaser shall be entitled
pursuant to this Section&nbsp;4.2(b)&nbsp;are referred to herein as &ldquo;<U>Public Information Failure Payments</U>.&rdquo;&nbsp; Public
Information Failure Payments shall be paid on the earlier of (i)&nbsp;the last day of the calendar month during which such Public Information
Failure Payments are incurred and (ii)&nbsp;the third (3<SUP>rd</SUP>) Business Day after the event or failure giving rise to the Public
Information Failure Payments is cured.&nbsp; In the event the Company fails to make Public Information Failure Payments in a timely manner,
such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in
full. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Public Information Failure, and such Purchaser
shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale of the Common Warrants or Warrant Shares underlying the Common Warrants or that
would be integrated with the offer or sale of the Securities for purposes of the rules&nbsp;and regulations of any Trading Market such
that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before
the closing of such subsequent transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a)&nbsp;by the Disclosure Time, issue a press release disclosing the material terms
of the transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form&nbsp;8-K, including the Transaction Documents as
exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release,
the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any
of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or
agents, including, without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents.
In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective
officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of
the Purchasers or any of their Affiliates on the other hand, shall terminate and be no further force or effect. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The
Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated
hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without
the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser,
with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure
is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement
or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name
of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such
Purchaser, except (a)&nbsp;as required by federal securities law in connection with the filing of final Transaction Documents with the
Commission and (b)&nbsp;to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall
provide the Purchasers with prior notice of such disclosure permitted under this clause (b)&nbsp;and reasonably cooperate with such Purchaser
regarding such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section&nbsp;4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall
not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of
their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, not to trade
on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant
to a Current Report on Form&nbsp;8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant
in effecting transactions in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Use
of Proceeds</U>. Except as set forth on <U>Schedule 4.7</U> attached hereto, the Company shall use the net proceeds from the sale of
the Securities hereunder for working capital purposes and shall not use such proceeds: (a)&nbsp;for the satisfaction of any portion of
the Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices),
(b)&nbsp;for the redemption of any Common Stock or Common Stock Equivalents, (c)&nbsp;for the settlement of any outstanding litigation
or (d)&nbsp;in violation of FCPA or OFAC regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section&nbsp;4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers, shareholders, agents,
members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;Purchaser Party&rdquo;) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result
of or relating to (a)&nbsp;any breach of any of the representations, warranties, covenants or agreements made by the Company in this
Agreement or in the other Transaction Documents or (b)&nbsp;any action instituted against the Purchaser Parties in any capacity, or any
of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such
Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings
such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws
or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct.
If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such
Purchaser Party shall promptly notify the Company in writing, and, the Company shall have the right to assume the defense thereof with
counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of such Purchaser Party except to the extent that (i)&nbsp;the employment thereof has been specifically authorized by the Company in
writing, (ii)&nbsp;the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii)&nbsp;in
such action there is, in the reasonable opinion of counsel a material conflict on any material issue between the position of the Company
and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more
than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y)&nbsp;for any settlement
by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed;
or (z)&nbsp;to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s
breach of any of the representations, other Transaction Documents. The indemnification required by this Section&nbsp;4.8 shall be made
by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred.
The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against
the Company or others and any liabilities the Company may be subject to pursuant to law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at
all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Listing
of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading
Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares
and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market.
The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include
in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares
and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action
reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with
the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules&nbsp;of the Trading Market. The Company agrees
to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing
corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing
corporation in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reserved</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsequent
Equity Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
the date hereof until 30 days after the Closing Date, neither the Company nor any Subsidiary shall (i)&nbsp;issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii)&nbsp;file any
registration statement or any amendment or supplement thereto, other than the Prospectus Supplement, any registration statement contemplated
by the Registration Rights Agreement or any registration statement on Form&nbsp;S-8 in connection with any employee benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
the date hereof until 180 days following the Resale Effective Date, the Company shall be prohibited from effecting or entering into an
agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which
the Company (i)&nbsp;issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive additional shares of Common Stock either (A)&nbsp;at a conversion price, exercise price or exchange rate or other
price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the
initial issuance of such debt or equity securities, or (B)&nbsp;with a conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent
events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii)&nbsp;enters into, or
effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;,
whereby the Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually
been issued and regardless of whether such agreement is subsequently canceled; <U>provided</U>, <U>however</U>, that, after 30 days after
the Resale Effective Date, the entry into and/or issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with the
Placement Agent as sales agent shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive
relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, this Section&nbsp;4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall
be an Exempt Issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is
also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers
as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition
or voting of Securities or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short
Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time
that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section&nbsp;4.4.&nbsp; Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section&nbsp;4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information
included in the Disclosure Schedules (other than as disclosed to its legal and other representatives).&nbsp; Notwithstanding the foregoing
and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i)&nbsp;no
Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of
the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial
press release as described in Section&nbsp;4.4, (ii)&nbsp;no Purchaser shall be restricted or prohibited from effecting any transactions
in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated
by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.4 and (iii)&nbsp;no
Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries,
or any of their respective officers, directors, employees, Affiliates or agent, including, without limitation, the Placement Agent, after
the issuance of the initial press release as described in Section&nbsp;4.4.&nbsp; Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the
portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capital
Changes</U>. Until the one year anniversary of the Closing Date, the Company shall not undertake a reverse or forward stock split or
reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority in interest of the Shares
other than a reverse stock split that is required, in the good faith determination of the Board of Directors, to maintain the listing
of the Common Stock on the Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers
in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required of the Purchasers
to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise
the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions
and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Form&nbsp;D;
Blue Sky Filings</U>. The Company agrees to timely file a Form&nbsp;D with respect to the Common Warrants (and underlying Warrant Shares)
as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action
as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Common Warrants (and underlying
Warrant Shares) for, sale to the Purchasers at the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of
the United States, and shall provide evidence of such actions promptly upon request of any Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Registration
Statement</U>. As soon as practicable (and in any event within 30 calendar days of the date of this Agreement), the Company shall file
a registration statement on Form&nbsp;S-1 (or other appropriate form if the Company is not then S-1 eligible) providing for the resale
by the Purchasers of the Warrant Shares issued and issuable upon exercise of the Common Warrants.&nbsp; The Company shall use commercially
reasonable efforts to cause such registration statement to become effective within 60 days following the Closing Date (or 90 days following
the Closing Date if the Commission performs a &ldquo;full review&rdquo;) and to keep such registration statement effective at all times
until no Purchaser owns any Common Warrants or Warrant Shares issuable upon exercise thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&nbsp;V.</B></FONT><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination</U>.&nbsp;
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been
consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such
termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fees
and Expenses</U>. The Company shall deliver to each Purchaser, prior to the Closing, a completed and executed copy of the Closing Statement,
attached hereto as <U>Annex A</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the
fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any
exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities
to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via
email attachment at the email address as set forth on the signature pages&nbsp;attached hereto at or prior to 5:30 p.m.&nbsp;(New York
City time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day
or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (c)&nbsp;the second (2<SUP>nd</SUP>) Trading Day following the
date of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom
such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages&nbsp;attached
hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial
Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and
adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser
relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected
Purchaser. Any amendment effected in accordance with this Section&nbsp;5.5 shall be binding upon each Purchaser and holder of Securities
and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser
(other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations, warranties, and covenants
of the Company in this Agreement and the representations, warranties, and covenants of the Purchasers in this Agreement. This Agreement
is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of,
nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.8 and this Section&nbsp;5.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the
obligations of the Company under Section&nbsp;4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page&nbsp;were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and
the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law
would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or
any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so
by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between
and among the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents
is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have
been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc.</U></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business
Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference
to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.21</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,&nbsp;IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages&nbsp;Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>CYCLACEL PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><U>Address for Notice:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Spiro Rombotis</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Spiro Rombotis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">E-Mail:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: President &amp; CEO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">With a copy to (which shall not constitute notice):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">CYCC
</FONT>SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 15%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name of Purchaser:</FONT></TD>
    <TD STYLE="width: 85%; border-bottom: black 1pt solid; font-size: 10pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>Signature of Authorized Signatory of Purchaser:</I></FONT></TD>
    <TD STYLE="width: 67%; border-bottom: black 1pt solid; font-size: 10pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 21%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 79%; border-bottom: black 1pt solid; font-size: 10pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid; font-size: 10pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 26%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Email Address of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 74%; border-bottom: black 1pt solid; font-size: 10pt"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________<U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prefunded Warrant Shares: <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</U>Beneficial Ownership Blocker <FONT STYLE="font-family: Wingdings">&uml;</FONT> 4.99% or&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U> Beneficial Ownership
Blocker <FONT STYLE="font-family: Wingdings">&uml;</FONT> 4.99% or <FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">CYCC
</FONT>SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 15%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name of Purchaser:</FONT></TD>
    <TD STYLE="width: 85%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Lind Global Fund II LP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>Signature of Authorized Signatory of Purchaser:</I></FONT></TD>
    <TD STYLE="width: 67%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Jeff Easton</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 21%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 79%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Jeff Easton</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 80%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Managing Member</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 26%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Email Address of Authorized Signatory:</FONT></TD>
    <TD STYLE="width: 74%; border-bottom: black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $<U>643,331.65</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: <U>84,250</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prefunded Warrant Shares: <U>109,850</U> Beneficial Ownership
Blocker <FONT STYLE="font-family: Wingdings">&uml;</FONT> 4.99% or&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: <U>194,100</U> Beneficial Ownership
Blocker <FONT STYLE="font-family: Wingdings">&uml;</FONT> 4.99% or <FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>7
<FILENAME>tm2333683d1_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&#8239;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.3</B></P>

<P STYLE="margin: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of December&#8239;21, 2023, between Cyclacel Pharmaceuticals,&#8239;Inc., a
Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages&#8239;hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant an exemption from the registration requirements of Section&#8239;5 of the Securities
Act contained in Section&#8239;4(a)(2)&#8239;thereof and/or Regulation D thereunder as to the Common Warrants, the Company desires to issue
and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company
as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,&#8239;IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&#8239;I.</B></FONT><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section&#8239;1.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section&#8239;4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section&#8239;3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule&#8239;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&#8239;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section&#8239;2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i)&#8239;the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)&#8239;the
Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second
(2<SUP>nd</SUP>) Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Warrants</U>&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section&#8239;2.2(a)&#8239;hereof, which Common Warrants shall be exercisable immediately at an exercise price equal to
$<B>3.19</B>, subject to adjustment therein and have a term of exercise equal to seven years, in the form of Exhibit&#8239;A-1
attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C., with offices located at 919 Third Avenue, New York, NY 10022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&#8239;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section&#8239;3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section&#8239;3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals $<B>3.315</B>, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section&#8239;3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&#8239;144</U>&rdquo;
means Rule&#8239;144 promulgated by the Commission pursuant to the Securities Act, as such Rule&#8239;may be amended or interpreted from
time to time, or any similar rule&#8239;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&#8239;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page&#8239;of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any significant subsidiary of the Company, as defined in Rule&#8239;1.02 of Regulation S-X under the Securities Act, and shall,
where applicable, also include any direct or indirect significant subsidiary of the Company, as defined in Rule&#8239;1.02 of Regulation
S-X under the Securities Act, formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, the Pink Market, OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, LLC, the current transfer agent of the Company, with a mailing address of 6201, 15th Avenue,
Brooklyn, New York 11219, and an email address of LegalTeamUS@equiniti.com, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&#8239;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&#8239;(New York City time) to 4:02 p.m.&#8239;(New York City time)), (b)&#8239; if the OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;)
or the OTCQX Best Market (&ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&#8239;if the Common Stock is not then listed or quoted
for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the Pink Open Market (&ldquo;<U>Pink Market</U>&rdquo;)
operated by OTC Markets,&#8239;Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of the Common Stock so reported, or (d)&#8239;in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&#8239;II.</B></FONT><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally
and not jointly, agree to purchase, up to an aggregate of $26,374.14 of Shares and Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">a
Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of such Purchaser&rsquo;s
Subscription Amount divided by the Per Share Purchase Price, with an exercise price equal to $<B>3.19</B>, subject to adjustment therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, as applicable, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">this
Agreement duly executed by such Purchaser; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">such
Purchaser&rsquo;s Subscription Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing
Conditions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on
the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which
case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in
all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
delivery by each Purchaser of the items set forth in Section&#8239;2.2(b)&#8239;of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein in which case they shall be accurate in all respects or, to the extent representations or warranties are qualified
by materiality or Material Adverse Effect, in all respects) as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
delivery by the Company of the items set forth in Section&#8239;2.2(a)&#8239;of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">there
shall have been no Material Adverse Effect with respect to the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&#8239;III.</B></FONT><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part
hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section
of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsidiaries</U>.
All of the Subsidiaries of the Company are disclosed in the SEC Reports. The Company owns, directly or indirectly, all of the capital
stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital
stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe
for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction
Documents shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority
to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary
is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i)&#8239;a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii)&#8239;a
material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company
and the Subsidiaries, taken as a whole, or (iii)&#8239;a material adverse effect on the Company&rsquo;s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document (any of (i), (ii)&#8239;or (iii), a &ldquo;<U>Material Adverse
Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke,
limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)&#8239;as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&#8239;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&#8239;insofar as indemnification and contribution provisions may be limited by
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which
it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i)&#8239;conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii)&#8239;conflict with, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)&#8239;subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&#8239;and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Private
Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section&#8239;3.2, no registration
under the Securities Act is required for the offer and sale of the Warrants or the Warrant Shares by the Company to the Purchasers as
contemplated hereby.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Warrant or
Warrant Shares by any form of general solicitation or general advertising. The Company has offered the Warrants and Warrant Shares for
sale only to the Purchasers and certain other &ldquo;accredited investors&rdquo; within the meaning of Rule&#8239;501 under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i)&#8239;as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&#8239;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&#8239;insofar as indemnification and contribution provisions may be limited by
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.
Such Purchaser understands that the Warrants and the Warrant Shares are &ldquo;restricted securities&rdquo; and have not been registered
under the Securities Act or any applicable state securities law and is acquiring such Securities as principal for his, her or its own
account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities
Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute
or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation
and warranty not limiting such Purchaser&rsquo;s right to sell such Securities pursuant to a registration statement or otherwise in compliance
with applicable federal and state securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Warrants, it will be an &ldquo;accredited investor&rdquo; as defined in Rule&#8239;501(a)(1), (a)(2), (a)(3), (a)(7),
(a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded, (i)&#8239;the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii)&#8239;access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii)&#8239;the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment.&#8239; Such Purchaser acknowledges and agrees that
neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with
respect to the Securities nor is such information or advice necessary or desired.&#8239; Neither the Placement Agent nor any Affiliate
has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may
have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided to it.&#8239; In connection
with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial
advisor or fiduciary to such Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>General
Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at
any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company acknowledges and agrees that the representations contained in </FONT>this Section&#8239;3.2 shall not modify, amend or affect
such Purchaser&rsquo;s right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations
and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection
with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of
doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing
shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&#8239;IV.</B></FONT><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
Restrictions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities
other than pursuant to an effective registration statement or Rule&#8239;144, to the Company or to an Affiliate of a Purchaser or in connection
with a pledge as contemplated in Section&#8239;4.1(b), the Company may require the transferor thereof to provide to the Company an opinion
of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably
satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the
Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and
the Registration Rights Agreement and shall have the rights and obligations of a Purchaser under this Agreement and the Registration
Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Purchasers agree to the imprinting, so long as is required by this Section&#8239;4.1, of a legend on any of the Securities in the following
form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">THIS SECURITY HAS NOT BEEN REGISTERED
WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY&#8239;NOT BE OFFERED OR SOLD EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE&#8239;V.</B></FONT><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Termination</U>.&#8239;
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been
consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such
termination will affect the right of any party to sue for any breach by any other party (or parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fees
and Expenses</U>. . Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without
limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered
by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a)&#8239;the time of transmission, if such notice or communication is delivered via
email attachment at the email address as set forth on the signature pages&#8239;attached hereto at or prior to 5:30 p.m.&#8239;(New York
City time) on a Trading Day, (b)&#8239;the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages&#8239;attached hereto on a day that is not a Trading Day
or later than 5:30 p.m.&#8239;(New York City time) on any Trading Day, (c)&#8239;the second (2<SUP>nd</SUP>) Trading Day following the
date of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&#8239;upon actual receipt by the party to whom
such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages&#8239;attached
hereto.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and each Purchaser. No waiver of any default with respect to any provision, condition or requirement
of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the
rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the prior
written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section&#8239;5.5 shall be binding
upon each Purchaser and holder of Securities and the Company.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser
(other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the
obligations of the Company under Section&#8239;4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such Action or Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page&#8239;were an original thereof.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and
the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law
would be adequate.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or
any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&#8239;etc.</U></FONT>&#9;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If the last or appointed day for
the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may
be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule&#8239;of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference
to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,&#8239;IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages&#8239;Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>CYCLACEL PHARMACEUTICALS,&#8239;INC.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><U>Address for Notice:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Spiro Rombotis</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="width: 46%"><FONT STYLE="font-size: 10pt">Name: Spiro Rombotis</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="width: 49%"><FONT STYLE="font-size: 10pt">E-Mail:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title: President &amp; CEO</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">With a copy to (which shall not constitute notice):</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">[PURCHASER SIGNATURE PAGES
TO <FONT STYLE="text-transform: uppercase">CYCC</FONT> SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser: <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U>_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
<U>____________&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;_______</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: <U>_____&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;______________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U> Beneficial Ownership Blocker
<FONT STYLE="font-family: Wingdings">o</FONT> 4.99% or <FONT STYLE="font-family: Wingdings">o</FONT> 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">[PURCHASER SIGNATURE PAGES
TO <FONT STYLE="text-transform: uppercase">CYCC</FONT> SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser:________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
 _________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory:_______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </U>
Beneficial Ownership Blocker <FONT STYLE="font-family: Wingdings">o</FONT> 4.99% or <FONT STYLE="font-family: Wingdings">o</FONT>
9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>8
<FILENAME>tm2333683d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm2333683d1_ex99-1img001.jpg" ALT="" STYLE="height: 100px; width: 269px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Cyclacel Pharmaceuticals Announces Registered
Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">December 22, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">BERKELEY HEIGHTS, N.J., Dec. 22, 2023
(GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;), a
biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it has entered into a
definitive agreement for the purchase and sale of 388,200 shares of the Company&rsquo;s common stock (or pre-funded warrants in lieu
thereof) at a purchase price of $3.315 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct
offering priced at-the-market under Nasdaq rules. The Company will also issue unregistered warrants to purchase up to 388,200 shares
of common stock with an exercise price of $3.19 per share which will be immediately exercisable for a period of seven years
following issuance. The closing of the offering is expected to occur on or about December 26, 2023, subject to the satisfaction of
customary closing conditions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In a concurrent private placement, the Company will also
issue an aggregate of 7,956 shares of common stock at the same purchase price of $3.315 per share and warrants to purchase up to 7,956
shares of common stock with an exercise price of $3.19 per share to members of management.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Ladenburg Thalmann &amp; Co. Inc. is acting as the exclusive
placement agent for the offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The gross proceeds
from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $1.3
million. The Company intends to use the net proceeds from this offering for working capital and general purposes.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt">The shares of common stock, pre-funded
warrants and shares of common stock underlying the pre-funded warrants (but not the warrants or the shares of common stock underlying
the warrants) described above (other than the shares to be sold to members of management) are being offered pursuant to a &ldquo;shelf&rdquo;
registration statement on Form S-3 (File No. 333-274328), previously filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
and declared effective on September 13, 2023. The offering of such shares of common stock and pre-funded warrants is made only by means
of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement
and accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the prospectus
supplement, when available, may be obtained on the SEC&rsquo;s website at http://www.sec.gov and may also be obtained by contacting Ladenburg
Thalmann &amp; Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt">The warrants described above are
being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered
under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not
be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This press release shall not constitute
an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities
in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>About Cyclacel Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Cyclacel is a clinical-stage,
biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis
biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the epigenetic/anti-mitotic program
plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified
biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional
information, please visit <FONT STYLE="color: Black"><U>www.cyclacel.com</U></FONT>.</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>Forward-looking Statements</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This news release contains
certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from
historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel&rsquo;s product candidates,
the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans
regarding partnering activities. Factors that may cause actual results to differ materially include, without limitation: interim results
of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as
patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including
the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; the risk
that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale
or later clinical trials; potential delays in the commencement, enrollment and completion of clinical trials; Cyclacel may not obtain
approval to market its product candidates; the risks associated with reliance on outside financing to meet capital requirements; the
potential effects of the COVID-19 pandemic; and the risks associated with reliance on collaborative partners for further clinical trials,
development and commercialization of product candidates. You are urged to consider statements that include the words &quot;may,&quot;
 &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot;
 &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot;
 &quot;designed,&quot; &quot;goal,&quot; or the negative of those words or other comparable words to be uncertain and forward-looking.
For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on
Form 10-K, as amended, and other periodic and other filings we file with the Securities and Exchange Commission and are available at
<FONT STYLE="color: Black"><U>www.sec.gov</U></FONT>. Such forward-looking statements are current only as of the date they are made,
and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Contacts</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Company:</FONT></TD>
    <TD STYLE="width: 85%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Paul
    McBarron, (908) 517-7330, <U>pmcbarron@cyclacel.com</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Investor Relations:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Grace Kim, <U>IR@cyclacel.com</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&copy;
Copyright 2023 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel</FONT><FONT STYLE="font-size: 10pt"><SUP>&reg;
</SUP></FONT>are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cycc-20231221.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaOIWbOdzZR+iYkxtmB4bRma3yYmWfPg0yxa/jn2kdUO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:cycc="http://cyclacel.com/20231221" elementFormDefault="qualified" targetNamespace="http://cyclacel.com/20231221">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://cyclacel.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20231221_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20231221_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cycc-20231221_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cycc-20231221_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cyclacel.com/role/Cover" xlink:href="cycc-20231221.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_deiDocumentInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cycc-20231221_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cycc-20231221_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cyclacel.com/role/Cover" xlink:href="cycc-20231221.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cyclacel.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="loc_deiDocumentInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiDocumentInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiDocumentInformationLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2333683d1_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2333683d1_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !_ &<# 2(  A$! Q$!_\0
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M?VY/@%_P55^//P\^!?[9W[6/P8\ :3_PJ^72? WPI_:,^,/P]\':5)=?LX_
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MO>>'M?T:XWDL1IVJ:==6MJ^YA)8Q6L@9M^2 <18MM8[T:2(#$BJ@D;8TMN)
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M/_K+O[/5?S4R_P"M?_>-?TK?\'6__*8;]HG_ *Y_"G_UEW]GJOYJ9?\ 6O\
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M,0\HI7^^-<Y(VK@R2J\,:M]PLZ.Q+YR-JI&Y((*N=NY253'^3W_P=._L,_\
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GW\0V[_L[? %;B#Q-_:W@B;29)=3\2-8OX=OH[2WT:.\NQK!0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm2333683d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2333683d1_ex99-1img001.jpg
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MWHDCQ:$'$!@AIEPC(4W0K@WHW_'R9"+MA R'9R(8V:(#(O,""MS"@1(I>$5
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M-H38D?\*?@"(BU?0)[XR6,]W?GA-&YUS0C$FX3S.P:(0.I#&-B+-D&.PHIG
M(,A!$F"-EKSD$."8(3/,[%12,%<V6/63) I =W>HH0GW4*_G&(!I#0Q4F;!'
M CXY\ BM) "R $ V,ST@8@^#86P\"$DQ%"D]M]Q"+JD(RX=10'"8C(UEIDE-
M$W)2EYZD&[C$100I$ $*L'+#D,[XRT8L<P&K' ();FDT JCM"-8CP **T,OK
M:8!0N^-A,<&0*<0YQXE<.&<RB0#":&JR"]?<91B$M,WT":T2#Q6@U%!9!J/-
ML ]:1%P8O*A0 'C1A">+S0+PR85]?J&=)#@F 11IA(S>"PS_;(S-%Q*:S2A0
MK3IEB0(>;X6.C/11#!XH "#]@,C!A2&>!6"I%LU82)&2M*2Q&2H8R#A/26(3
M"475:!AB>E NT+0,4S!":(PX&)Z)2 !7 T DJ/:%#@Q4$>V<YQAR^5(PH2=E
M0T J2[M@TBY8M6'H>><1VBE8F!+2"U\E0UA! U&;1(%5&=$:2,H@4T>D\:U>
MR"K2<CG07#+U"WWEPC'Q2@'G8!8 :>3A%[@ZTSB"U9N,95!.!2"4C,!*MF3(
M@ 89$=+"BJ&><HVG5 ' I[WR-:IBZ&==^PG0%:&,#*Q%K&L5V]@X5;>LM!U"
M1IB%VV;4LZ[0=8Z?!)=4YU*1#*%-_T([9^C%IUJUN5L]+$*G.P8[SI:.M]*/
M )A5!6^TLZ/\1%D[=YO7]&[!P$>@*CV=0^!BT=>P@T168NOK&2/<BHXR$TJ'
M\"@-_XH7#>UTCER+(%ST(A<,5FTP[\Y;A/^&-\)O?' 8^C&,ZP+ 8S?K[C4\
M')L&DZ&1!+CH(A&,!"(30:5/S>4J73P&KDY1PC(&@SB. -LA!,)<IW22 'A\
MU3/$DP"?+?")Q6!D(2CW"%8%+P"8+(;HSK>39>C8$;)1!)9\*A+HT%7[A*%%
M-9>!JT\50DBQ1^8Q=Z&=Z11"&O%93_A"N*M;F+ 8JE.>G_@*K=9EU6&Z$4_?
M_EF^1WB.D/^/N\4OI/&&$^03#P?]8D@G0=)A"->> 3 9\:$/$;JJG$ZZ8<LT
MN/D(*@TSJ8>+!*MF4IY%4'6301WI*+LOE$8@%[$ $(BF@ 0>!S"7,'(Y8C/\
M6D]7+'2I-WAL41,AEP8(]!:^_6IG?R$;GQH"%-(Z/N0-H2 HD=H2?]%/K7J;
MV49(XTC#8&3F5O/@I36JF>W59H C =9A^ F].693-51<WFRBT?.8D7#9J-L+
M["Z"L1=@W"(;6KVFY<**"8!7&MKKXT8(^1$@;B<IL/56?62)N3K$+.S$&QAD
M<N4]C^ !U19!YN<VTP2,2P("&YF,G@;VA^,G]$ 7W:"MA7,96"?_&"',>YN[
M'H)=<(0 O2TCZ.FA8-,>($5B#P'I24_/ D@(,0= ,XQ4;)K>(=8PJPK;"%;M
MMGF\V#NZ3X#MXV:<@/:N=RQ>4^V,+Z$7</-S (3&.)$PEP$WKJ"NA>$9^^Y#
MQ]OH]J:Z&@E[RB01,ND[E9;<",4U0HBGV&TG3Q%IUVPC@(NPI"/(;-JZNALH
MX\T51W'A)ES*! D41_IU.QRK41PDH5@/@'X*?@L=%_;R^80A0BO>DKC/Y.Z!
MHTTC_(1JD>7]JUX"D@BPU6 @,;XF%%C#"58PT42H?^F34'08HK"$^(1J-S0_
MGR-!IT5T$^1H)!9!]B<!JZ1_ MA!0Z!#_Q&X0U] >4> /M,V'WU4$&9W,Q P
M '- '! 0"(; %R)P._1C*S9W!.C2/X#1/_OA>2\A',1Q)4; %>.T@@0""MJF
M%6Y 1]"S#3"( %-A!F9!+3Q8*W$1=NHG #^5$9RG%5P1(6(@+0VRA+7B@T@0
M"<)79Z>T1"# $MGV?FJ  5"P$5JX+4U8,.^193E(A!G(.>10'(K!! P !4@Q
M3AZA@FN8&5QX!',S;4,(A4FP#]?0#@T@*3M(:\[RARQX<6(5!3\U&$%HAF7
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3H DC2X"3[5(%DD(IISD000  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140274163438640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 21,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-50626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CYCLACEL
PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001130166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1707622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200
Connell Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Berkeley
Heights<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">517-7330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CYCC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Preferred
    Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CYCCP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tm2333683d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cycc-20231221.xsd" xlink:type="simple"/>
    <context id="AsOf2023-12-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <context id="From2023-12-212023-12-21_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <context id="From2023-12-212023-12-21_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001130166</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2023-12-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-12-21">0001130166</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2023-12-21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-12-21">2023-12-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-12-21">CYCLACEL PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-12-21">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-12-21">0-50626</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-12-21">91-1707622</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-12-21">200 Connell Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2023-12-21">Suite 1500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-12-21">Berkeley Heights</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-12-21">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-12-21">07922</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-12-21">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-12-21">517-7330</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-12-21">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-12-21">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-12-21">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-12-21">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-12-212023-12-21_us-gaap_CommonStockMember">Common     Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-12-212023-12-21_us-gaap_CommonStockMember">CYCC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-12-212023-12-21_us-gaap_CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2023-12-212023-12-21_us-gaap_PreferredStockMember">Preferred     Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-12-212023-12-21_us-gaap_PreferredStockMember">CYCCP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-12-212023-12-21_us-gaap_PreferredStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-12-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " "C2YI7EXJ[',     3 @
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MY68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B?
M:ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G6
M0VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_
M,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    " "C2YI7)!Z;HJT   #X 0
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I
M0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LID
MR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\
M./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6
M?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ HTN:5V60>9(9 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( *-+FE>F]#7;[@   "L"   1
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M96QS+RYR96QS4$L! A0#%     @ HTN:5ZK$(A8S 0  (@(   \
M     ( !^Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *-+FE<D'INB
MK0   /@!   :              "  5L2  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( *-+FE=ED'F2&0$  ,\#   3
M  "  4 3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  (H4
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2333683d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cyclacel.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cycc-20231221.xsd</File>
    <File>cycc-20231221_def.xml</File>
    <File>cycc-20231221_lab.xml</File>
    <File>cycc-20231221_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2333683d1_8k.htm">tm2333683d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>22
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2333683d1_8k.htm": {
   "nsprefix": "cycc",
   "nsuri": "http://cyclacel.com/20231221",
   "dts": {
    "schema": {
     "local": [
      "cycc-20231221.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "cycc-20231221_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cycc-20231221_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cycc-20231221_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2333683d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "report": {
    "R1": {
     "role": "http://cyclacel.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-21",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2333683d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-21",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2333683d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cyclacel.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>23
<FILENAME>0001104659-23-129018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-129018-xbrl.zip
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M*,_W/7VR*(XP4Y=<1!<XA G5B?Q.("4AP8$%%!1CK,R0R5BS7U$K)Q4RQO5
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M8?>8@GKP52/0=G,UO?P+4$L#!!0    ( *-+FE?;6,M5T @  ,!I   5
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MHHVS44'G4+/^-E*' F7P^2C[L@PE+5672$MR(=-(OO 0J;2'=#(*0(3Y;5C
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M?[$J%:Z==4HT59./:N]FC_ZE_Q&$VO(/4$L#!!0    ( *-+FE?YX-$KZ2$
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MCU*L<==Q 045WQGMD@-PJ6Z)"E-ZCF4:KXEXV75\WQG*]TKX/FLF7&/%,W^
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MC9 [RTBS46Z,<FEP)""7]Y 9)B:H$CH= 49!K=Q1F^!-,1[IN<Z0(275K5C
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MY&%B H6<#B,S7]NVV.E;@7SF?T\&U&846Q8I#7S"ZD-Q#G:-KL\XA6W1Q/3
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M?#P?;'=/S\S+;:OW_IW]Y]'M=XZ._P=02P,$%     @ HTN:5\G>U1%Q/P
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MW_*Z="(*8/@M)B />GS5J Z&I0[$'7Y^%._N[D9;Q/7K=DE:&[#RK#@K24J
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MYTP!]\&XX+Q6P*<I:BS7P+O@CK;PODGJNDPS"2'_66:P(&>P*FT%BT<[ ]?
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MD?&C7^.C?Y='!S4U1\::.# ZRW&&G ].%8,8X85/S(;55_21U+GD\)+F)N]
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M90/H"-,^@5[(?BY%/7?QVV ML55DW9.KE\0]]1JVR7O'LJ)D/ JQ]*;X';!
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MA(-VXR&/(:.^3+_<8#;R%\ ]86=NEHY'G\AP1E;^P4(Z\P:_LK[M88=PP.=
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MLK)X.R@G!R=LVBT%LM9A_2C/VUT/SAQ8OQ(4X>@VSF%P..NEWW^RM[>E)-!
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M,N-C77^;%,Z5;]"OR+(6B!3OB_S;]%T&7W&A%B4PEVF[L*'0,"'A034=*'K
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M9AR)SBE(;N!7*:L"CXTU4W32#[M=M>*##IP\XS1M"K-C8#S-EKDN\\!3>NQ
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MO;T?U.UM$)L)&G<RIH ,"O:9E,ZU?K^:$QO"')L0CTF\-%)A#S5WW!5H]3G
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MJ'2%;6XN%H ='H7V7/3=]?KP>4[;9X?/=D:[>]%1H_2--6MCR\:KW6EW8_O
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MW\=L=(F;47)PKJ8N$\;Y'UO8*G?OZ<3^K Y%$_P.DWPDL2MZNG= XWO_@S6
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M( C\N=%%5K4V""]&=T<7R>U*/AI2W<6P1.708^A5,=UGSQPZE-[(70E%%+_
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MH'F3,=V!>)!/0*_(R[DRNRXS4;R#R!\&RFJ0/^LN *<JX"69247/0+?S-U7
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MHW5K\7IG(E%HDNG,T9_VAJ!-R$;?8@0OR9>J,_ (&.4PG0<N5_$D609.F>%
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M#F9?T:,7JN1#I]GRG^NR#^WJ!>0+WEE/+GV7D+<: ]0/'^TY&$?W2A#RQ_K
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M5 H],2-,.K7[H6O#(V78+<C*70\!:=<ZA<F56(>E9!$*ZK0M4)W9PK0.]IZ
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M'L<B:WZ38S]YOT8W&0@ 6'@V7=1^Y"1<W'8,F6Z_U8;@4(-MQ.9O)VQW!^W
MDG>,.K8'438^T1@5MMV@EQ(R:_=O?5\(T?(I*["17(@^3RS0I'R:7+A[IC<=
M7)^$88>2%3'1ITN8=G>#%.H 6<B=ND/ V!(<GR1@'KP^^>??Z./[AK;:;0/R
M&8'C<H<?J6AZRPZ];6'F=)DVL YO$V&H]YY&[8,D&YD?*,5K3E^7XC]$*D"=
M(P+'Q=X)W+R$Q'Q,OP==U\,>T@K#'^PD&(8'8R[!2#?_]ZG\]QO$L>,_OI4/
M7LA_#PXIJ8?^^72W%Y<7K87E;?>YW>?I/>_STX]85]44$@D+=9$^O=755DAR
MJ1[;E-<,8W NCQ85$]^0=%Q4'G5=SJ?HVE06N5&=@8VIJRPH;FJF1ZHQR3.Q
MB">$NXPX5FNKQ,OU-(,616^JLOJ#.WR6U3HCNB\\'S.I,=@ZO'S#T A*V[@<
M\;ZV:9B^P5[E$7M*_4[XF)AQ692S;$RM<+RYVZ< ^0*OC"VTQ^H='-53[2>3
M"=8Q2ESUH"@OZ]Y.;@_FG0?3W//!/"(247)GGWG>IEY+LEO1-VMHPTX3WJ?E
M'%.G%H4XXBO#JO1*E[,N& 77BOE(13\D>%>/IR;%G"G6I9MRUQ/IG1Y+FE;M
M-%%.%*>=B&&-@!>QU:\$-C_M3$K-YE20VHY%"FX[9S<72W+IF40W!'_6MR@:
MD)@U[C#"M>"$4A[$"@IV&(MCD*E]W4\<R+!'.[>#[Q,&0OGCT8K^AP$%&:TU
MT<!I6M011C#ZDO>\+'1=C8G"&3G[B7[:Y?_Y6C5Q4,%&Y9 *^:#4G5'L=A2S
M(6&2\1\B_"2<9*6'91X+^?]::UN."/_/I:93[G.+!M89N[X*0UUC-1?.-$:0
M$!F6QO%.+@H%KS.XQT@UQVNDJ(T AQ" Y"(DQ%3[P;" E8HW2M*F9DQ.X-ZL
M."4OA3UKW3DD50_IDVKI1Z$20]J5;2U*]*A-&-)^<)HH_%Q; ;7VFYY4;#B]
MR9SGHS4F=:5@'[+:7@U]+?AI),:I&A.I^HC$[AP=H[DL&1LN2"W<5J'SJ&['
MWR4=BR IGB@LO!=[NV"IROT$4XU[)E(>2TY8419/I,*&GH"^O>  013@:BV$
M+'MA3"I^%H5Y1*I'.VEG*PH:(UY:\[^I :+9VM+'-ME8XG52^>:X @EG^")8
MTXD4$&BPVC7S>4VR=#'.Y."T(G\/7F?8, CR]38(PD&0K[=!D$>EL4[NFSR;
M<_R&@R!M/Z'BP9[YW2%F%(C8X4"<+K82*J&R/%I25^H^Q;8HG%2Q7)URB=P9
M+;[$P"/*@K\M;?O1QA[&0(J+/,XD'U2B$@/U5J>^G**B<DD?2RX!RWG-;Q+J
MJDP'SN8>K'<IM/P@L5%'=X^37XKTJ-;D3#(8EJ+E3#C]I)XB%^^.)>DDH9_D
MNY&KAMJNN\B .YY3=UNW:TS5IFF$#U,N-$=93$JVJSJVP3*S7X#7(YLQ8Z;)
MER'$UN-VV)N&E<8:7#VWE/@4RJ;KD@"ZUJ*VP-1$396E2TFB&:C3V1/6E ,U
M\<; M9\;KOV+B!2D44.E E7>"<C[4O3KJI9_A(]8TZ+?08UP0*)NL\I,3ZL2
MP[%._@X)0X].*PJ78(U6]91."4/_[^YIQ!UEP']+>?-9^V#'0&<9]4@IPN@<
M[R>>D%?2DE#3PX&=_E7]YO6BH:T8.#9N3V1;G5*)/A1<.+*$IV&20PE;5FW]
MVO.FAK]B=]C*P$/;+78'E3X%Q#@5SA$L87H= ZD*^I1+-GMTCRAO(64Z<1/R
M?O(:8*\ 574_<*;&H>"VA394-@\N4&I8K>W/HH#Y4>>\782(X(VD9]!N]Z40
MPY_MWG6DAP/+Z)#<E%EJM>>T7(SH2L!L\FO%^\SX7-F5'AA&(9]@'V.ZB427
MF.<:5@'ZSSPM(KOB8#.3SR8OQXF-3()J6%$-0$MOA8GP%?G(2S1;\0"H.T%C
M\@()*3Z$R0+KR#]\_?O/UX"N[UD#$E:(X:!+"]'U J-E*&*I'P&26&)O2YHM
M; TD:;!X>X.74.RHM5=4-@^CM4&D$TQ=2M^3G-'"W-;S9(Y:SBRY3OZ3L7_?
M[D6Z?&D_5V62CK$H"5.2F=PP=H["\$F:E7)0:JZ@@]X/U@MF"(58R1[4A7^Z
M&NP;$EF8OX8W^\NF>?SCARM=<&.=%ZKGHJY#,GR9.Y*_;:X=D9:X<:F,%6:
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M3L/Q> ^GU#_\@/T>G\4G>J6U(>7(9$^>]F1J10Z5+@Y94_R[Y/^*&A<F](Q
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MI!W#A5C"H>UB$!HRPR.+/XJ?)'%,6[D/1;]8=D'3)'JU4[#04RJW1XHA@#B
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MD8DU@ $)WZIJ_H?_$5$<Z5!2-!%HUM2Z]+%U55P]9MO2^TFLP?3+R'"PPVS
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MS:M@'JB60.0?VZ>U8U[IWIB>(,M^6(::66$_[A G44JDGLHUOAA[LUQW<V3
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M?"%&#F?565[ X8SK51B3B_8'&.\HI\   T5812F<J_%K!3.?%ODYJ+<Q3CK
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M161=ZH >,)A704Y8)M)+BC!\W,-(1O#HA*1)> V9TR6QHH.B<%1?7T:A %<
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MPJ33$GN8U@1GFZT46 =GFF=DFE3YJ:9/K.O#5PO.\>51#2*9_"7++U(=G^H
MMM3T#%V<GEFNO<F ]*L5:OK0256%@<TRI_)%JG2,PBF#'HV5QM;CXG&@\&61
MB*Y>).47*^%-J1\Z&%@(3UAA;)X0K-70&^1F<#E'VL:FUW0#MAHL@L<T0M@
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M%/5PM7SNQZHQ5N_WWMY^;WN_WZ!&@-<"T7H*AC\8P,U$%9SHX&3[/^'Y,$!
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MZ)3"85>14RGI[>@ P"0/O*@@05IIA'\R+0?%ORL=#/$OTA-*%LZ71+!]W[+
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M,I_<9>_M%5NR;8EI=SZ8E;QJD]['U2-#<?GRW4A,W4M)U2=8!.-S6T:(AT"
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M);FRV$E<0'=LF>+=SCW[^9UGOUV\>OF\WWOVV_'^$?P;X7_/+DXN7AX_?_:
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M"'%8WY[[I0?Z6_@7W,%G#V#A+7LP!/)_?Y\5Y"= ZKBO[A1_:IDB[I6[[HY
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M4%K+?7/0TQJ _&&X7& D/$=[&*#5".)ZF7*Y*8:.,59&=/S3:[7I)*"[HH6
MS 7;%N@&,23.T2V FQ)V'0#""+==M@4G!#I!4[YV4B=12AL%R$DP3HQ@NWB\
MCIQ*2KPG+ENQ78N):6V1TTKV$,LN&Y>YY3+X4A1W8[T$X#;*VM<%IE4[WXN"
M^5E/%E\:/)$H2:M1J=ST NT,TD=(G0(KS='BSA9KR&9U<H#4!C?%_T8[&T[\
M6AMKNDM\_,YV"91@?N26H](:29NP_'4#%600.KO<O/R\<$/X\,)+U.*7(F@H
M88ITP1%L13Q:&M^HM\T[_9Z3A<>!8O<48A,U8\4.$T\6Y+7$VZ. "Q#WHY0W
M-PW$H)Q<BR^R9O 1C#&J@TR.39A\FIL)2S*!VQ#-K0QJUU0&UH!@5V1F*K*N
M\QH.>X\M[HM; 6XJU<UM<?%MN( H';'XS#$8R# VPB6-%GYH,KH&7 HE)7CL
M@AXXF4CP_E*9]R^ T$;XZF(!Q\CM,'TO.56&'[9^.\C;:'ZO;N9K8G44Q7Y)
MDJ_6%S5XC[/%6BUXJP/#>@YH@Y6T/8T2E;9R0Z>UFUL:I^\7OBH3-'9LF5&F
MK7)THT0G'YI'+^"$G6NV)^)F%&7PC%IN9(>52;30KN+AM+O4SH%-/0DL89TH
M[I?<K]>?JQ0Y!8E:ZG3DH@Q1_.0Z=^H*NP1H2"=V%#@IF:NYKUO 9S;ROW[=
M^?77!X_A_W[X;[T5;:>K;YM->7%GZ^91K3@/+Z[U,<:;FV$UD.P;N8Y^2L^
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MO4^D6$<?IU=[HGVU8CU>I5@WM_Y:6C/=X?5J<W-[5VG-]C EBZ%)'@U=N:O
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MCN"S041F1TO!S[H< R>H:/:LJ2KU>QVZ$@NK3+#OC/?>XNLXLT4(+0N+'"]
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MIO89#!Q'PQ)[VU$;3=T2!%^"QK=&&C5^73O6W?58VRK]ICK.&6:VCSYY2U9
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MRW2.W@9XC/"G;@?N$&],PB0-UN!9\F-85>'H LVY=34SAWDECH,>9\)N*4;
M\)R&Q[#="0/QS,3ZEVTS$>S;]PE,+=\.3OTT@:F!B]>2=5GBZ@KN^5C]9AW+
M[ ^O)>9*N$4V(VL3[N!<.8*9*9(R$</SM(*OAD4$@EF!I\WV[3$(:1Z12[;
MDXG6S=#8TEZWK 9MT\  C"\.(\5U+,,D8F^.'7\QT645Z8/P'(SI<[A!MZ/G
MFAPL\EKQ"C>:%933>(0AB4@M23B=IN"X#M/&=8,EOTI0HBA^B1-5!*.PO(!9
M_VM1XI+ 7%W$<)9'17B%XIJ!*+T#,84GP*Q5\,AAF*&CF,8EFVSX??I%OS#8
M8Z,XFL%SG.'Y4SE2\SB,8?K04EOP-MU._74VX17AR@\;.>Q9V!QITRMK_[6
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M$\K9A#SMV@'BOC):Z%1)4JD"81B2 HN;TA%.MC"QP0C/,H0N,US*P/!E4;7
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MSEG>L.@V6KGA@52!5_N:*^!><;O]P(O0*5&Y^-R5[#759DS#N?N>A%;%+Q.
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MAB;14Y-_#5]J\Y\-M*7<^5#B,&(9Q&P+^'ZV9_5G;C3?IG8SL3=4L6XPS3=
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M2)J'HU.*S]M0)'=K,6[08WX0]N]-V)4]VXJ8NEMK\45D76>]O@J*2WAV;@-
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MXA'L)>1X;-189GS=?/-S#7 6*<2'$LIR]?E6(0@M1F +03S-8@_1,)%&W,D
M<?+?C5T$89$@@C"=6K6"U43*G4IL+Y^5Z/2)SNJ!MS7D3HRJCW!,Y0LHS\@H
M2]<H[1JKSNVJSV[5,KUJ!59*<N--9*I$GI#16LUWM;?S0T/6LD0U!C6D@!B;
MK+?Z'09$'??4@S*>3EF[)/!<QFKE\^-'&2T<15@#+!V(A*M!J+$""6,-3<3L
M8A9]D>M,,S6QPK2OO-SH3*]PV=FM5@9$=;9 $(2'2D=C'&RD# @3KS0.?%(O
M(2PC71&/&S76:>:@WL\ -02'3,21=>KSV(2B7V_7A(Z\(/>)IA1#LD]BXC0!
MAO/4+MT^UX%""HYW16>/'.$(Z;_>>ONZW?IY,\?86:/K]?*M(G$$YKX83LM0
MKE;F*B\I!ZHX>P#&HC&O#(&)K_JY^W&9GR!SF67*QU[&?OJN#7TA]DB(REA:
M)8VEJV> &KP)#.=AHU"P' ($@AD=7"693?O-MDW[S"#-DX2C>38[N[7%W#:E
M-?8G5E1),R4-E+%QD\-)7K=>;P_+AZ43\F&6$.#0 2ET]!BL"LC/=U8K<P&=
M$;]?-(MY@"JPJ@NFPB@X 'D -L()L8 4M\:E"X&6S>*P[#Z0WC:",AU4EK%Q
M782U8T1T/FU-^)+L)CE*S>NZYLS "%OCA= \4Y\C9J"^"&#ANWRV-<%JA?%*
M_*!*&D(D.B)5XZO5XR@WD4XGUJC+"8OX&/5[K@W33#F-7,#,XDVC"<ML[W,:
M @[RP*&@_NNBN6SPCN(R9_6 ;)*FX%DR5BSH\*',T&U0YLHDUI-J; B#:!F)
MX*)XM?*UF&8@<< ZGYN[)F(.SME$,C,G )"39KS4R<&'QB^TJV!,R626.^:V
MWIU!YN566!?K+#H' 6*1JZ34 RJOR&40J$_C*^7. T2UXQTKU]<='A7"R8Y+
M<G.-;Y^6-CILOS(I@1%!U 9-YG>CG!%.J:4=H5JSE1#JM7F!5N,ZS\5:BZFU
M-$ZF*.[2<F"&)%TGW8J3V,+BK"1HC#941Z@7"4@>% 5U>U8N#B_P@!Q%%61*
M1]+J%:*FN4>X@;P^>/NQE[.[U(JM="1<A2K$<2)?,E\+21U!H78Y"0T0$H/?
M<G]L!422AP$!5FFF))-,$%83HT&1*RD5V4J'/<BHF>L5[C;WM:$*XOM=<<PK
M/>M@@@Z1R\#Y73J'1 D%B''>HFDDG1J7X!6/(,92]&("49SA-+Y*2";T(U-Q
M1R EHJPNQ_$Y&\0?X4!6I1R(UKJ.1'APL5F,593#C2+HF_4@<]R-T'_H;,JA
M4Z)S3?4XDEG.=6O$5]@]@\PA$RIO%&[?; G4-PQUEMETES-L9K ]+(+E"#4=
M[<:2$J9AK&_2LJAW@GB(=]*;UJC50 +/UA^.>Y$2U.DZR8>!]BQ.-$M6)#8_
M!W1I.P3[PWHW%>E>SNY$JWR #VA9<_9[BM1$06Q&@/Q'4O/":2RE:8&+Z[/2
MBT[$&#8*[+;5@X<Z;&9?@G$H?65!R]9.YN%T*5<X)]AYT:"^0GPIHH/+>PLY
M&1T$U53KSO<>RC(RJ%9.2ZUS3][/TF/F D318^^*SZH@72X""AL\4$ZGM)QQ
M]K<AD2*X-1QJ1@"*XIO; +C^1O+8X%&M.*,ME1ATB2AYIWVR'QO-<+]MZPR&
MLN8;?$CB/%(^G8PB+&<2D<ZK.LA3$X;J42XNBEKG11MYB6#WXE-!,I$^-7@'
MXBVMA/'Q_U ,D;J4L:/JDP %KVCL[F,!P*#]'_+\P,Z5UXV![B32&W%(0SA_
MW9-)ZK:B](A2BFP'2$RH$3UD\ZVCDSC-BE;V\;^]&)Y^C)8P4.DFZXM)\R9K
M^TB*7:W&\8:+JY5S J5.O8UV9+&!;C9:*C[+= (39]32/F^1^B=,N'7T\>)R
M\-^:Z)U]NKA$/7=Z]>&R)L[/;FXN^C7QOG?UJ?_K%W%\V1775]=G5S5QO7NZ
M4F7O <G/-H LB/ZK7A?G6@7^@;B68W6(];_G"O$!9$6][I[*E9VH_&2GV5KS
M:.<-W7-.5=RS?M6<>]7\#"7)RKY;''>9_= H>5L?*K@"9$Q8YK)(;]9(1&(^
ME65),7ND&:N,EQGQ3F1:U*N4*4@UXQA>8)N%(G&X/!)H5#T<Q5$"J8Q69Y-J
MA4MDKNTH_;BD-LM9E*6*$:Z=[M$T1T5VYD9<N%?D3AJ%$XP_SS&/]!]NF((3
M(KG:/A?Y2?)LVXVZOC%HF;==?*MTV9^-72"J1B4U5#0BUCX2O!6V)D9Y@*M$
M:M_ET0@)DQH.Y%T[_+45_MH))I_?ST' %F KX[ER.6:KS,79AB@*+SF6U M!
MD&EHBP+<'U''DRXIQ2ELW;#EQRB+%P[1S/"P%67MV$)G9:JNJ.SV%%<LQ7G*
MOZ\'AD;'IDP(;990.I31K<F3C&IOT(D#%*KT?61D#GVSAC@;*H-8"@V:L8QF
MU3#UF<@8.@]+K2;759!X;*NX67FE RKA>6KB!BZD=5L>TZ0-=M,@EKKNW3ZI
M=9/M>$:-ZFMJ<]";(JM!D:[BMW-[TL+B&-UAQ[D,EVP$0;+X5_R'E;0ZQ2^C
M<1'B@,H&&'_..FZSN2%/XM!,T:0+X).WU I"/JZ"[1,MG%)#QS0\=)&%I[&S
MZKR(<FC?K24\;= CH7:%RE)Q&\7W4='26>Q;HMS%$%6NS&WSRJ7S#-5VCG"G
M4S1I5 W/![=926Q>-*()K"V?60X:F2R(P2$SE%/N,^0HX_@6<C5/4PXJXB,[
M0S%,QL[K>0I"%.DV0$OA9X5.3)WIWV$(]YG;\53-G\;PM)K*BT(/(VW"TM04
MU1(KQ4UX>VI,+=='.R\IGCH50?#[IO-6D!$\GQ\?+<PV>'9&@R/[JLV:1TC5
MRHS<BVZ"^E )-!U,:_^\*/3HBT*/%ZJSEW+V&S]M'>VE>^(CO5:#2AYA LQ/
MXPG^GBMC-&1X'\1WZ>U4O)(A6I'K.%%Q4<JOO@!4)EQZ3:AX46>S4ZQYP6@=
ML>=^ZV>AG1'KNQFGA'(_\W+=Y6\Z,WB6R4 Q'XC\IZU_VCSAZ5.%[Y@M?.^$
MX9^IP9.F!L\]A/AKYAFM0W'%U45Z('H2[<F+&6_\=;.&/7J'VKY43>]>_Q]0
M2P,$%     @ HTN:5TDR&?L?#P  /C<  !8   !T;3(S,S,V.#-D,5]E>#DY
M+3$N:'1MY5M9<]LX$GY7E?X#UC63L:LD^<KE8UPKVTKBC>-X;6>F\K0%D9"$
MA"08@+2L^?7[=8.D*%F*G1GGV)T\Q"($-!I]?MV@]E]=O3D]:#;V7_6ZQ_@K
MZ-_^U<G5:>]@?]W_Q;?KQ=?[AV^/WXO+J_>GO5]7!B;)=L7F1IJ)*QTK)\[4
M6%R86"8M/] 2E\KJP0H68NEYN2Y3-UE;1GJ8[ JKAZ-L3\32#G72SDRZ*S:J
MQ[[),A-C9.5@__"@=S/2?9V)G9W.YO[Z(=@[GR-\7X;F]DNSVSNFV<K!HZ3O
MTKVOOLW^B[=G5W7:[8&,=339O8LZSW7Z#^69 :63-R_%Y<411!QO;6]O/WV^
M'6[^1]WL[+0W=3S<V-CL?$B'*Z)[>O7KRDJYY4B1#HC&1GJS)\8ZS$:[8NOI
M3GH#DNO$W?>6==]$X0,*_/#@:!)$,E"1.!])&^-3GNE 1DYTD\3D28 ]+M10
MNTQ9%38;Q]JJ(!,R"<6YU=<R4^*<UL<JR<3;P0";)T/Z*E"AZ&;MJY%JOY'V
MH\K$NR145IQ)%\I/XB*/E/M_LMUC!2'T<<"MK9;8VMC:_FX'JP>5#[G+]&#B
M/>0!]S[L7;SNG?;>BU>]DY>OKBY;XJSSKTY+0 J=2@+-QNK+T[>'/7'6^_WR
M]Y.+WIIHM\4R@VN)DP2+5\^ZE\?=?^^*H_='1R!;>SK?$X\^Y2;;*TGX)V&L
MR$:J_,[$J4PF_F&M)62ST=<FG=E+!'Z2"-6UBDQ*)JMA[C!G?:U$K$(=Z 1"
MZDL',S:)""0\P0KL&0F0B\QP M*%AX0B,Z&<@ F9"83ED70"[D . [*9(1Y"
M-=")9O)R:)7WET'!>9K; (L4NY63D1)F(+:?/V]M;6P(!];!"D9H:GD\ZW#
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M&O4:P@5E]MLZZN>.A%^3/O"/3A6TRY$/ZH+&0YM3/R )=<@95X8AA6Q&3DG
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M_T$<_6[NOU!+ 0(4 Q0    ( *-+FE?  [,,-P,  -D,   1
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M;3(S,S,V.#-D,5]E>#$P+3(N:'1M4$L! A0#%     @ HTN:5[K6?.(>/@
MX7D! !8              ( !DS4! '1M,C,S,S8X,V0Q7V5X,3 M,RYH=&U0
M2P$"% ,4    " "C2YI7?D;ZW$E!  !7>P$ %0              @ 'E<P$
M=&TR,S,S-C@S9#%?97@T+3$N:'1M4$L! A0#%     @ HTN:5P:4-S O2
MZ9D! !4              ( !8;4! '1M,C,S,S8X,V0Q7V5X-"TR+FAT;5!+
M 0(4 Q0    ( *-+FE>YFZ..P0L  ((M   5              "  </] 0!T
M;3(S,S,V.#-D,5]E>#4M,2YH=&U02P$"% ,4    " "C2YI723(9^Q\/   ^
M-P  %@              @ &W"0( =&TR,S,S-C@S9#%?97@Y.2TQ+FAT;5!+
4!08     #  , "$#   *&0(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
